INDEX TO VOLUME 175

Author Index

Aach, R. D., 458
Abbas, A., S62
Abderrazak, S. B., 655
Abrams, E. J., 707
Ackermann, B., 1121
Adeyemo, O., 218
Adkins, A. R., 84
Afif, H., S71
Agopian, M. S., 1302
Agut, H., 1198
Agwu, D. E., 146
Ahmad, A., 38
AIDS Clinical Trials Group Antibody Selection Working Group, 1056
Aiura, K., 123
Aiyama, T., 505
Åkerblom, H. K., 554
Akue, J. P., 158
Akuffo, H., 737
Alak, J. I. B., 218
Alam, R., 497
Alberici, F., 255
Albertine, K. H., 847
Alcala, A., 828
Alexander, J. P., Jr., S62, S176
Alfieri, C., 38
Alford, C., Jr., 1080
Ali-Salaam, P., 1000
Allander, T., 26
Allard, A., 1523
Allemon, M. C., 172
Allen, R. C., 1184
Allendoerfer, R., 905
Allies, T., S30
Alugupalli, K. R., 1515
Alm, P., 611
Almirón, M., 1272
Alonso, P., 921
Alvarez, G., 828
Alves, F. P., 1544
Alving, C., 764
Amselem, S., 292
Anda, P., 1243
Andersen, P., 1251
Andersen, P. L., 474
Anderson, J. F., 98
Anderson, L., 1225, S264
Anderson, L. J., 195
Andersson, A.-S., 1285
Andree, B. C., 989
Andrus, J. K., S37, S89
Antinori, A., 1193
Araneo, B. A., 821
Arditi, M., 1255
Arif, M. A. M., S235
Aristizabal, G., 828
Armstrong, R., 992
Artenstein, A. W., 265
Artese, L., 703
Arthur, J. D., 756
Arthur, M., 598
Asher, D. M., 441
Ashkenazi, S., 1128
Aslangul, E., 598
Aslanian, R., S50, S62, S205
Ast, J. C., 482
Astier-Gin, T., 716
Aubert-Combiescu, A., S241
Aumont, P., 316
Aylward, R. B., S56, S86, S97, S117, S173, S183, S194, S268, S277
Bach, A., 681
Bach, S., 1531
Backenson, P. B., 1243
Bakhiet, M., 669, 737
Bakshi, S. S., 1039
Balfour, H. H., Jr., 1087
Ballard, R. C., 583
Ballou, W. R., 915
Balotta, C., 1210
Baltimore Area Polio Vaccine Study Group, S228
Bamji, M., 707
Banerjee, K., S89
Banuls, A.-L., 655
Banya, W. S., 200
Baptista, M., 598
Barakamfitiye, D., S10. S16
Barbosa, L. H., 458
Barbour, A. G., 91
Bardin, N., 1142
Barela, T. J., 373
Barnes, R. C., 1259
Barthold, S. W., 1000
Bartlett, M. S., 482, 661
Barzgar, M. A., S205
Basolo, F., 693
Bassett, D., S173
Bassetti, D., 255
Bates, J. H., 1446
Be, T. V., 450
Bean, N. H., 876
Beck, H.-P., 921
Beck-Sague, C. M., 583
Belisle, J. T., 1159
Bellini, W. J., 195
Belshe, R., 764
Benach, J. L., 1243
Benard, G., 1263
Bendtzen, K., 1508
Bentley, D. W., 342
Bergelson, J. M., 697
Bergeron, M. G., 176
Berman, P., 764
Bernier, R., 176
Bernstein, H. H., 444
Bertino, J. S., Jr., 678, 1494
Besen, G., 1308
Besser, T. E., 726
Bethel, J., 1029
Bettinardi, A., 272, 1026
Beuvery, E. C., 441
Beveridge, A., 1502
Beyene, A., 26
Bhagani, S., 164
Bhattacharya, S. K., 1134
Biberi-Moroeanu, S., S241
Biellik, R. J., S10, S20, S24, S30
Bilous, J., S117, S97, S173, S194, S268
Binh, T. V., 450
Birkett, A., 1294
Birmingham, M. E., S4, S10, S146, S183, S286
Birx, D. L., 265, 292, 1352
Bistoni, F., 1467
Bittorf, T., 669
Bjøro, K., 938
Black, H. R., 638
Blake, M. S., 364
Blakeley, D., 16
Blanchard, A., 955
Blanchard, S., 716
Blandón, S., 545
Blau, N., 130
Blegvad, S., 474
Bloch, C. A., 983, 989
Bloch, S., S62, S198
Blostedt, M., 737
Blum, L., 1198
Bock, P., 1368
Bockenstedt, L. K., 1000
Boelaert, J. R., 1467
Bohannon, N. J., 648
Bohnsack, J. F., 847
Boivin, G., 1087
Boivin, G. P., 905
Bokete, T. N., 1382
Bolan, G. A., 1519
Bold, G., 1063
Bolding, F., 992
Bollinger, R. C., 1360
Bolton, W., 1510
Boman, J., 1523
Bonafonte, T., 1302
Boner, W., 1093
Bonsel, G. J., 1344
Boom, W. H., 429
Boone, G., 1039
Bopp, C. A., 1527
Boshell, J., 828
Boucher, C. A. B., 966
Boucher, S., 655
Boulos, M., 1544
Boursnell, M. E. G., 16
Bouvier, B., 992
Bowden, R. A., 1012, 1459
Bowen, S., 1423
Boyle, M. D. P., 1115
Bozzette, S. A., 302
Bradac, J. A., 1056
Braden, C. R., 1446
Bradley, W., 795
Brambilla, D., 567
Brandt, C. M., 233
Brennan, M. J., 1423
Brenner, C., 955
Brew, B. J., 963
Bridges, S. H., 1056
Briles, D. E., 839
Brinkman, B. M. N., 188
Britt, W. J., 1080
Britto, P., 1039
Britton, S., 737
Broome, C. V., 200
Brothers, K. S., 1352
Brown, A. E., 1352
Brown, D. W. G., 951, S156
Brown, E. G., 1548
Brown, J. J., 373, 983
Brown, K. E., 450
Brown, T. M., 707
Brown, Z., 606
Brunham, R. C., 1153, 1453
Bruzon, L., 828
Bryan, J. P., 915
Bryson, Y. J., 971
Bucci, P., 1467
Buisson, Y., 1198
Bulkow, L. R., 674
Buraphacheep, W., 935
Burchett, S., 971
Burda, S., 764
Bürgisser, P., 1202
Burke, D. S., 795
Burke, J. F., 123
Burkot, T. R., 466

Burnett, P. R., 265
Burns, D., 567
Burns, D. N., 1206
Busse, J., 77
Butterworth, A. E., 493
Buu, M., 450
Buurman, W. A., 108
Bwayo, J. J., 57, 833, 1153
Byabazaire, N., 947
Byron, J. W., 265
Caceres, F. M., 828
Cadeo, G. P., 272, 1026
Cadiz, R. B., 400
Cage, G., 876
Caldelari, I., 70
Calderon, L., 828
Calvez, V., 1198
Camacho, T., 828
Campbell, D., 1176
Campbell, G. L., 98, 1432
Campbell, L. A., 648, 883
Campetella, O., 1272
Camus, D., 655
Camussi, G., 693
Cantwell, M. F., 545
Cao, K., 168
Cao, X., 821
Capello, D., 1193
Capetti, A., 1210
Capparelli, E., 1039
Cappuccio, A., 648
Capraro, H. G., 1063
Carbon, C., 598
Carbone, A., 1193
Cardenas, V. M., 828
Cargnel, A., 255
Carithers, R. L., Jr., 1101
Carlone, G. M., 200, 84
Carman, W. F., 1, 1093
Carmody, L., 996
Carner, K., 91
Caron, F., 232
Carosi, G., 255
Carr, A., 966
Carrasco, P. A., S37
Carrick, R. J., 458
Carroll, K. C., 864
Carville, A., 1016
Casavilla, A., 448
Casola, A., 497
Cassar, O., 1497
Cassol, S. A., 1352
Castelli, F., 272
Castillo, C., S160
Castro, K. G., 1446
Castro, R. G., S160
Catacora, M., 486
Cave, M. D., 1446
Cenci, E., 1467
Cerutti, C., Jr., 1544
Chadee, K., 1176
Chaitt, D. G., 781
Chamaret, S., 955
Chambrin, V., 172
Chang, J., 1510
Chao, C. C., 478
Chatta, G. S., 1184
Chaudhri, G., 1480
Chaudhry, R., S205
Cheang, M., 1153
Chen, C.-Y., 1390
Chen, M., 1000
Chen, S. C. A., 414
Chen, S.-M., 856
Cheng, P.-W., 638
Chernoff, D., 247
Chernokhvostova, Y. V., 441
Chervenak, K. A., 429
Chezzi, C., S24
Chiba, Y., S105
Chierchini, P., S86
Chigurupati, P., 764
Childhood Diabetes in Finland (DiMe) Study Group, 554
Chiodo, F., 255, 966
Chisholm, S. E., 16
Cho, I., 444
Cho, S.-Y., 1280
Chohan, B., 833
Choi, W.-Y., 1280
Chou, S., 1087, 179
Christner, R., 1115
Chu, C., 959
Chudaiberdiev, Y. K., S82
Chulay, J. D., 915
Chung, D., 330
Chungue, E., 1497
Church, L. W. P., 915
Cillari, E., 142
Ciraru-Vigneron, N., 172
Clark, A. M., 648
Clark, B. D., 123
Clark, S., 1333
Clausen, C. R., 1382
Clements, M. L., 764
Clements-Mann, M. L., 1494
Clerici, M., 1210
Clinch, T. E., 821
Cloud, G., 1080
Clyde, D. F., 915
Cochi, S. L., S1, S71, S183, S198, S210
Cohen, D., 1128
Colebunders, R., 1283
Coleman, P. F., 458
Colizzi, V., 1531
Colletti, P., 142
Colman, K., 1093
Colombo, M. C., 1210
Combiescu, M., S241
Conaldi, P. G., 693
Concia, E., 255
Connell, H., 611
Conrad, P. A., 1259, 1432
Conti-Fine, B. M., 382
Conway, B., 576, 801
Cooley, J., 795
Coombs, R., 237
Coombs, R. W., 247
Cooper, D. A., 966, 1502
Corey, L., 1101
Corey, L. for National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group, 247
Costales, M., S272
Costes, O., 1051
Courvalin, P., 598
Cowles, M. K., 971
Coyle, P. K., 689
Coyle, S. M., 118
Crawford, M., 400
Cremoni, L., 255
Crowell, R. L., 697
Crumpacker, C. S., 790
Cruz, J., 756
Cryz, S. J., Jr., 871
Cummings, F., S277
Cummins, L. M., 283
Cunningham, A. L., 1510
Cunningham, J. A., 697
Cunningham, P., 963
Cutler, J. E., 1169
Cysticercosis Working Group in Peru, 486
D'Agostino, P., 142
Dale, D. C., 1012, 1184
Dalibart, R., 716
Damiani, E., 1527
D'Ancona, F. P., 142
Dangor, Y., 583
Daniel, T. M., 1535
Dankert, J., 1020
Dankner, W., 1080
Danner, S. A., 1344
Darnell, M. E. R., 932
da Silveira, C. M., S37, S43
D'Aversa, G., 462
Davey, R. T., Jr., 781
Davis, D. A., 1071
Davis, J. R., 915
Dawson, G. J., 458
Daza, E., 828
de Alencar, F. E. C., 1544
Debanne, S. M., 1535
Deepe, G. S., Jr., 905
de Groot, R., 1413
De Gruttola, V., 237
DeHart, D. J., 146
Dei-Cas, E., 655
de Jong, M. D., 966
de Kleijn, E. M. H. A., 191
De la Hoz, F., 828
De la Hoz, O., 828
de la Luz Sanchez, M., 545
Delfraissy, J. F., 172
Deloria, M. A., 1494
Demacker, P. N. M., 191
Demeter, L., 247
Demetris, A., 448
Deming, M. S., S254
Demmler, G. J., 1080
de Neeling, A. J., 1413
Dentener, M. A., 108
Depardieu, F., 598
Depraetere, K., 1283
de Quadros, C. A., S37, S43, S160, S189, S281
Derouin, F., 1020
de Saint Martin, J., 955
Deskin, R. W., 497
Devaney, E., 158
de Vries, P., 524
de Waal Malefyt, R., 118
Dhruva, B., 1360
Di Alberti, L., 703
Dianzani, F., 255
Diaz, C., 712
Diaz, L. A., 828
Dick, E. C., 1108
Dienes, H.-P., 1121
Diethelm-Okita, B. M., 382
Dietrich, S. E., 876
Dignat-George, F., 1142
Dille, B. J., 458
Dimock, K., 1548
Dinarello, C. A., 123
Dobbins, J. G., 136
Dodson, F., 448
Dolei, A., 693
Dornan, E. S., 1093
Dotevall, L., 720
Dowdle, W. R., S113, S286
Dowling, A., 179
Dragunsky, E. M., 441
Draženović, V., 32
Drenth, J. P. H., 191
Drew, W. L., 179
Drummond, W. K., 864
D'Souza, M. P., 1056
Duarte, A. J. S., 1263
Dubey, J. P., 1280
Duffy, L., 1440
Duliege, A.-M., 764
Dulski, K., 214
Dumler, J. S., 720
Dumoulin, F. L., 681
Duncan, I. A., 16
Dunne, D. W., 493
Dupin, N., 1198
Durand, I., 655
Durlacher, R. R., 1544
Dussaix, E., 172, 944
Eberhard, M. L., 1259
Eckert, L. O., 1453
Edelman, R., 915
Edwards, R. H., 1324
Eglin, R., 951
Einsele, H., 1490
Eissenberg, L. G., 1538
El-Bakri, M., 681
El-Bualy, M. S., S235
Elder, A. G., 1
El Kheir, A. A., S56
Ellen, J. M., 1519
Elmets, C. A., 947

Elzenaar, K., 1413
Endo, Y., 1404
Endtz, H. P., 729
Engelhard, D., 979
England, P. D., 775
English, B. K., 1008
Ennis, F. A., 756
Entenza, J. M., 70
Entwisle, C., 16
Ercoli, L., 1531
Erice, A., 1087
Ernst, P. B., 497
Escande, J. P., 1198
Eschenbach, D. A., 1453
Espinal, M. E., 1025
Estis, L. F., 790
Eugene, G., 944
Evans, J. S., 795
Excler, J-L., 764
Ezekowitz, R. A. B., 1159
Faden, H., 1440
Falcone, V., 693
Fallon, P. G., 493
Falloon, J., 781
Fantin, B., 598
Faouri, S., S62
Farhat, S., 927
Faruque, A. S. G., 734
Fasching, C., 975
Fattovich, G., 1093
Faulkner, G., 1101
Faverio, L. A., 932
Favorov, M. O., 1302
Fè d'Ostiani, C., 1467
Fehler, G., 583
Feig, K., 996
Felger, I., 921
Feng, N., 1317, 330
Feucht, H.-H., 685
Fields, H. A., 1302
Fikrig, E., 1000
Finberg, R. W., 697
Fiordalisi, G., 1026
Fiore, L., S86
Fischer, H.-P., 681
Fitzgerald, E. A., 441
FitzGerald, J. M., 1080
Flavell, R. A., 1000
Flavier, J., S272
Fleerackers, Y., 1283
Fleming, T., 237
Fletcher, C. V., 283
Fletcher, M. A., 621
Florendo, O. A., Jr., 342
Flores, G. R., 1432
Flores-Aguilar, M., 1308
Floridia, M., 255
Fontaine, R. E., S71
Forastiere, F., S86
Forman, S. J., 309
Forrest, B. D., 200
Forsgren, A., 1515
Fowler, M. G., 1039
Fowler, M. G. for Women and Infants Transmission Study, 567
Fox, K. K., 1396
Foxman, B., 983, 989
Fragola, V., 255
Frame, P., 302
Francioli, P., 70
Francot, G. J. M., 108
Frank, Y., 1039
Frankel, S. S., 1352
Frasch, A. C. C., 1272
Freeman, C., S264
Freeman, W. R., 1308
French, M., 966
Frenkel, L. M., 971
Freymuth, F., 944
Fries, L., 915
Friis, S., 743
Frisch, M., 743
Frissen, P. J., 966
Fritsche, T. R., 1382
Fritz, C. L., 1432
Fulford, A. J. C., 493
Fung, J., 448
Furlong, S. T., 661
Fusco, P. C., 364
Fusi, M. L., 1210
Fyfe, G., 781
Gaafar, M. T., S50
Gagro, A., 32
Gaidano, G., 1193
Galanos, C., 1284
Gallily, R., 979
Gallo, D., 1432
Galphin, J. C., 352
Gambino, G., 142
Gangan, P., 1308
Garcia, H. H., 486
Garcia-Monco, J. C., 1243
Garner, R. P., 265
Garofalo, R., 497
Gary, H. E., Jr., 136, S135, S141, S176, S264
Gayowski, T., 448
Ge, X.-M., 168
Ge, Y. C., 1510
Gebhardt, B. M., 821
Geiger, A. M., 989
Gelfand, J. A., 123
Gellin, B. G., 1494
Gendelman, H. E., 1368
Genn, W., 1502
Georges-Courbot, M. C., 716
Germann, D., 749
Gern, J. E., 1108
Gerneth, F., 1490
Gerstoft, J., 1508
Ghazizadeh, S., 847
Gheesling, L. L., 84
Ghosh, A., 1134
Ghosh, R. K., 1134
Giam, C.-Z., 947
Giannini, V., 255
Gibbs, C. L., 1004
Gibbs, P., 756
Gilbert, J. M., 1317
Gilks, C. F., 975
Gillespie, B. W., 989
Gilman, R. H., 486
Gil-Roda, C., 1087
Giorgi, J. V., 959
Giron, K. P., 590
Girot, R., 316
Gisslén, M., 434
Glauser, M. P., 70
Gloghini, A., 1193
Goedert, J. J., 63, 1071, 1206
Goldman, W. E., 1538
Gomez-Flores, R., 214
Gonzales, O. Y., 1527
Gonzalez, A. E., 486
González-Cappa, S. M., 1272
Gordeuk, V. R., 226
Gordon, D. M., 915
Gorin, I., 1198
Gorla, R., 272
Gothefors, L., 1246
Gotzsche, P. C., 1508
Gougeon, M.-L., 955
Goutte, G., 1063
Goyal, M. K., S71
Graceffa, R., 142
Graham, J. A., 756
Grandadam, M., 1198
Grangeot-Keros, L., 944
Granoff, D. M., 200
Granström, M., 720
Grayston, J. T., 883
Greenberg, H. B., 330, 1317
Greenberg, R. N., 678, 1494
Greenwood, B. M., 200
Gretch, D. R., 1101
Griffin, P. M., 633, 876
Grillner, L., 26
Grillo, G., 142
Grimes, V., 1333
Gritti, F. M., 255
Grogan, J., 494
Groover, J. E., 590
Gruber, W., 1080
Grubman, S. A., 1268
Guarnaccia, J. R., 891
Guenther, A., 421
Guétard, D., 955
Guichon, A., 470
Guigon, M., 1497
Guillemain, B., 716
Guiramand, S., 316
Gump, D., 678
Guo, Y., 839
Guris, D., 195
Gusdal, A., 1285
Gustafson, R., 720
Gutierrez, R. A., 458
Guyot, K., 655
Hadziyannis, S., 1093
Häeberle, H., 497
Hagberg, L., 434
Hagiwara, A., 1233
Hahn, P., 734
Hajjar, C., 716
Hale, A., 951
Hall, C. B., 814
Hall, D., 966
Hall, W. N., 876
Halsey, N. A., S228
Hamill, R. J., 590
Hamilton, F. G., 856
Han, Y., 1169
Hancock, D. D., 726
Hanover, E., 1527
Hanson, M. N., 1087
Happ, C. M., 996
Haque, R., 734
Harding, A. J., 1480
Haridi, A., S56
Harrison, L. H., 438
Harrison, S., 756
Harrison, W., 462
Hart, R. H., 1494
Hartmann, E., 77
Hassan, A., S56
Hatch, M. H., S43
Hatheway, C. L., 633
Hawes, S. E., 1453
Hayes, P. S., 876
Hazenberg, M. P., 729
Heath, J. L., 195
Hebart, H., 1490
Hechemy, K. E., 210
Helfand, R. F., 195
Hemming, V. G., 932
Henrard, D., 959
Hermans, P. W. M., 1413
Herold, M., 226
Heron, I., 1423
Herrington, D. A., 915
Hersh, B. S., S37
Hershow, R., 712
Herwaldt, B. L., 1259
Herzog, C., 871
Hessol, N. A., 1519
Hiatt, R., 1240
Hiemstra, P. S., 108
High, K. P., 222
Hikiji, K., 168
Hill, H. R., 847
Hill, J. M., 821
Hillier, S. L., 606
Hillyard, D. R., 847
Hillyer, G. V., 567
Hilton, E., 996
Hiltunen, M., 554
Hinshaw, V. S., 7
Hioe, C., 764
Hioki, K., 441
Hirsch, G., 283
Hoenderdos, E., 966
Hoffman, S. L., 915
Höjeberg, B., 737
Holder, P. F., 84

Hollinger, F. B., 458, 712
Holmes, K. K., 1396
Holsboer, F., 1284
Hommel, M., 158
Hong, C., 179
Honzumi, K., 700
Hook, E. W., III, 1396
Horowitz, H. W., 210
Hoshino, Y., 330
Hosoya, M., 700
Hossler, P. A., 482
Houghton, J.M., 1216
Houston, E. D., 590
Hovi, T., 554
Hoy, J., 966
Hrushesky, W. J. M., 1283
Hsu, L., 1225
Htun, Y., 583
Hu, R., 47
Hu, S., 478
Huang, J. E., 1012
Hubbard, B. S., 1337
Huber, W., 921
Hughes, J. P., 247, 648
Hughes, W. T., 901
Huh, W., 1280
Hull, B. P., S89, S113, S146
Hull, H. F., S1, S4, S62, S146, S183, S254
Humphrey, R. W., 1071
Hunninghake, G. W., 323
Hunt, N. H., 1480
Huovinen, P., 392
Huraux, J. M., 1198
Hutchins, W. A., 84
Hutwagner, L. C., 1527
Hwang, I. P., 821
Hyöty, H., 554
Ichiyama, S., 723
Idris, A. A., S205
Igarashi, H., 723
Iino, S., 168
Ilonen, J., 554
Imagawa, T., 1548
Imberti, L., 272
Imrie, A., 966, 1502
Inglis, S. C., 16
Ion-Nedelcu, N., S241
Ishida, S.-I., 1317
Ishikawa, T., 505
Iskandarov, T. I., S82
Isopet, J., 172
Ito, M., 1220
Iwata, K., 505
Izurieta, H. S., S24
Jack, R. M., 661
Jackson, D. J., 833
Jacobs, B. C., 729
Jacobs, R. F., 1080
Jacobson, L. P., 959
Jacobson, S. H., 26
Jaffar, S., 200
Jagodzinski, L., 795
Jahn, G., 1490
Jaiteh, K. O., S254
Janoff, E. N., 975
Janssen, R. S., 1225
Jarvis, W. R., 992
Jaster, R., 669
Jefferson, D. M., 1268
Jellinger, R. M., 561
Jennings, R., 16
Jewett, P. H., 807
Jian, Z., S122, S210
Jiang, X., 951
Jimenez, E., 283, 1039
Jin, D.-Y., 1229
Jing-jin, Y., S105, S210
John, G. C., 57
Johnson, B. J. B., 98, 996
Johnson, J. L., 947
Johnson, J. R., 373, 983
Johnson, S. A., 932
Johnston, S. L., 323
Joiner, K. A., 1159
Jozwiak, R., 1510
Judson, F. N., 1396
Julian, N. C., 146
Juto, P., 1523
Juvenale, M., 1263
Kahn, J., 764
Kakumu, S., 505
Kalidas, M., 214
Kalish, L. A., 712
Kalish, M. L., 707, 1333
Kaminski, R. W., 292
Kamiya, H., 1220
Kang, M.-W., 1280
Kanz, L., 1490
Kaplanski, G., 123
Karpman, D., 611
Kaslow, R., 959
Kasper, D. L., 1237
Katlama, C., 172
Katongole-Mbidde, E., 947
Katz, J. M., 352
Katz, M. H., 1225
Katz, S. L., S1
Katzenstein, T. L., 1508
Kauffmann, R. H., 966
Kazanjian, P. H., Jr., 891
Ke-an, W., S105, S122, S210
Keefer, M. C., 247
Keet, I. P. M., 188
Keisari, Y., 1128
Kelly, E. A. B., 1108
Kernbaum, S., 1198
Kersey, K., 292
Kestens, L., 1283
Keusch, G. T., 1268
Kew, O. M., S24, S43, S71
Keyserling, H. L., 678
Khan, M. A., S205
Kharabsheh, S., S62, S198
Khudyakov, Y. E., 1302
Kim, K. H., 1216
Kim, Y.-R., 1280
Kimani, G., 493
Kimani, J., 1153
Kindt, T. J., 1337
Kinoshita, T., 454
Kissin, E., 1004
Kjemtrup, A. M., 1259, 1432
Kjær, S. K., 743
Klaucke, D. N., S16
Klein, B., 1108
Klein, M. R., 188
Klein, R. S., 1025
Klimkait, T., 1063
Klingebiel, T., 1490
Kloczewiak, M. A., 621
Knapp, J. S., 1396
Knigge, M. F., 458
Knight, P. V., 1
Knip, M., 554
Kogelschatz, K., 749
Kohn, R. P., 1519
Kolbert, C. P., 98
Kollaritsch, H., 871
Komatsu, K., 876
Kong, F., 927
Koopman, J. S., 989
Korah, R. M., 1216
Korelitz, J., 1029
Kotler, D., 1016
Kovacs, A., 283
Kovacs, J. A., 781
Koziel, H., 661
Kreiss, J. K., 57, 833
Krieger, J., 57
Kriesel, J. D., 821
Krohn, M. A., 606
Kropff, B., 533
Kršulović-Hrešić, V., 32
Kruize, Y. C. M., 1276
Krystofik, D., 1440
Kulczycki, J., 689
Kumah, S., 200
Kumar, M. L., 678
Kunz, C., 871
Kuo, C.-C., 883
Kurniawan, A., 1276
Kwak, N.-H., 1280
Lacke, C. E., 590
Lackner, A. A., 184, 1016
Lafeuillade, A., 1051
Lambert, G., 707
Lambert, J. S., 283
Lambert-Fair, M. A., 876
Landay, A., 567
Landers, D., 971
Landesman, S., 712, 1206
Lane, B. R., 482
Lane, H. C., 781
Lane, R. S., 98
Lange, J. M. A., 966, 1344
Larocca, L. M., 1193
Larsen, K., 474
Larsen, S. A., 466
La Seta, F., 142
Laskus, T., 448
Lathey, J. L., 231
Latif, I., S205
Lau, J. Y. N., 168
Laue, N., 233
Laufs, R., 685
Law, M. G., 963
Lazdins, J. K., 1063
Le, T. P., 915
Leach, A., 200
Lebon, P., 944
Lederman, M. M., 429
Lee, C. A., 164
Lee, F., 1333
Lee, J. W., S4
Lee, R., 448
LeFebvre, R. B., 400
Lefrère, F., 316
Lefrère, J.-J., 316
Leguizamón, M. S., 1272
Leifeld, L., 681
Leigh, M. W., 638
Leinikki, P., 554
Leininger, E., 1423
Leisenring, W., 1459
Leitz, G., 966
Lemon, S. M., S247
Leonard, D. G. B., 947
Leonard, R. B., 864
Lepri, A. C., 775
Lerable, J., 316
Lesaule, G., 1142
Levenbook, I. S., 441
Lew, J., 712
Lewis, D. C., 951
Li, J., 1233
Li, Z., 1115
Liang, X., 91
Li-bi, Z., S105, S122
LiButti, D. E., 200
Liles, W. C., 1012
Limoges, J., 1368
Lin, D. Y., 237
Linares, M., 1527
Lindh, M., 1285
Lingwood, C. A., 77
Linkins, R. W., S146, S210, S235, S254, S258
Linscheid, P., 130
Liska, S., 1225
Litwin, C. M., 864
Livnat, D., 1056
Lobanov, A., S10, S16, S30
Locht, C., 1423
Lodhi, Z. H., S205
Löffler, J., 1490
Loftis, L. L., 1008
Logan, L., 545
Lohmeyer, J., 421
Loiselle, P. M., 621
Lokar-Kolbas, R., 32
Londos-Gagliardi, D., 716
Long, C. E., 814
Long, N. T., 1233
Longhi, R., 1210
Lönnrot, M., 554

Loomis-Price, L., 292
Louder, M., 1352
Lowell, G. H., 292
Lowry, S. F., 118
Lu, X., 352
Lubaki, N. M., 1360
Luckey, C., 947
Ludwig, G., 828
Luke, C. J., 91
Lundborg, M., 1523
Lundeberg, J., 938
Luquetti, A., 1272
Lyerly, D. M., 734
Ma, N., 1480
Maasho, K., 737
Mabeza, G., 226
Mach, M., 533
Macklin, M. D., 7
Maclean, I., 1153
Maes, E. F., 195
Mahafzah, A., S62
Maher, C., S97, S117, S194, S268
Maher, K., S264
Mahon, B. E., 876
Maizels, R. M., 1276
Majid, M. A., S62, S198
Malankar, P. G., S235
Maldonado, Y. A., 545
Mancino, G., 1531
Mandaliya, K., 833
Mandelbaum, S., 462
Mandelbrot, L., 172
Manning, M. C., 342
Mansfield, K. G., 184, 1016
Mansour, E., S56, S277
Mansueto, S., 142
Margolick, J. B., 959
Margolis, N. H., 123
Mariani, F., 1531
Marino, I., 448
Mariotti, M., 316
Märker-Hermann, E., 1121
Markus, I., 1128
Marrs, C. F., 983, 989
Martin, G. M., 16
Martin, H., 1490
Martinez, J. W., 828
Mascola, J. R., 1352
Masur, H., 781
Mathiesen, D. A., 98
Mathieson, B. J., 283
Matsui, S. M., 545
Matsumoto, T., 205
Matter, L., 749
Maulden, S. A., 821
Mawle, A. C., 136
Mayaux, M. J., 172, 944
Mayumi, M., 454
Mazars, E., 655
Mazzotta, F., 255
Mbori-Ngacha, D., 57
McCarthy, M. G., 1259
McCartney-Francis, N., 1004
McClain, D. J., 756
McConnochie, K. M., 814
McElhaney, J. E., 342
McElrath, M. J., 247, 764
McGovern, T. W., 915
McGregor, M. W., 7
McIntosh, K., 567
McLaughlin, G. L., 661
McLean, C. S., 16
McLellan, C., 971
McMahon, B. J., 674
McQuitty, M., 992
McRae, E. M., 726
Mdurvwa, E. G., 218
Meadows, L., 1333
Meals, E. A., 1008
Medany, M. A., S235
Mehta, F. R., S235
Mehta, P. D., 689
Mehta, R. T., 214
Mehta, S. P., 689
Melcher, G. P., 795
Melgaard, B., S4
Mellemkjær, L., 743
Melvin, A. J., 971
Mencacci, A., 1467
Mendes-Giannini, M. J. S., 1263
Mendez, H., 567
Menezes, J., 38
Menozzi, F. D., 1423
Merigan, T. C., 179, 561
Mertz, K. J., 1390
Meschievitz, C. K., S228
Meshnick, S. R., 482
Mestan, J., 1063
Metcalf, J. A., 781
Metzger, D. W., 84
Meyer, W. A., III, 283, 1029
Meylan, P. R. A., 1202
Michael, N. L., 1352
Michon, F., 364
Miedema, F., 188
Mikusova, K., 1159
Milazzo, F., 255, 1210
Milhous, W., 1544
Milich, D. R., 1294
Millan-Velasco, F., 545
Miller, N. S., 1243
Miller, R. H., 511
Mills, K. H. G., 1246
Milstien, J. B., S247
Mindell, D. P., 482
Miner, R., 179
Mintz, E. D., 1527
Miranda, E. T., 1263
Mitchell, C., 971
Mitchell, P. D., 98
Mitchell, R. M., 1206
Mix, E., 669
Miyakawa, Y., 454
Miyake, K., 454
Miyamura, T., 1233
Miyazaki, S., 205
Mizokami, M., 168
Mlinarić-Galinović, G., 32
Moazed, T. C., 883
Mochny, I., S89
Modlin, J. F., 697, S228
Moers, D., 1446
Mofenson, L., 1039
Mofenson, L. M., 283, 1029
Mohan, K., 971
Molitor, T. W., 478
Money, D. M., 1453
Monick, M. M., 323
Montagnier, L., 955
Montaner, J. S. G., 576, 801
Monteiro, D., S258
Montesano, C., 1531
Morand-Joubert, L., 316
Moreillon, P., 70
Mori, C., 1548
Moroni, M., 255, 966, 1210
Morris, S., 179
Morse, S. A., 583, 1390
Mosci, P., 1467
Moscicki, A.-B., 927
Moseley, S. L., 1382
Moser, S. A., 1538
Moses, S., 833
Mosley, J. W., 458
Moss, B., 927
Mossa, A., 693
Moulia-Pelat, J.-P., 489
Moye, J., Jr., 283, 1029
Moye, J. for Women and Infants Transmission Study (WITS), 712
Moynet, D., 716
Mu, L., S105
Mukaide, M., 168
Mukhopadhyay, A. K., 1134
Mulders, M., S62
Müller, C. A., 1490
Muller, M., 414
Mullington, J., 1284
Munguia, D., 1308
Muotiala, A., 392
Murai, T., 723
Murante, B., 971
Murgue, B., 1497
Murphy, G., 1246
Murray, H. W., 1477
Mushahwar, I. K., 458
Musher, D. M., 590
Mustafa, E., 669
Mutin, M., 1142
Nagai, Y., 505
Nagelkerke, N. J. D., 833
Nahm, M. H., 839
Nahmias, A., 1333
Nair, G. B., 1134
Nakagawa, M., 927
Nakamura, M., 1404
Nakano, T., 168
Nakao, H., 454
Nakashima, K., 723
Nam, H.-W., 1280
Nareth, L., S173
National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group, 1080
Ndinya-Achola, J. O., 57, 833
Nduati, R. W., 57
Nelson, R. P., Jr., 63
Nemo, G. J., 283, 458
Nesheim, S., 1333
Netherlands Fever of Unknown Origin Study Group, 191
Neumann, V., 7
Newcomb, F. M., 1071
Newman, G. W., 891
New York City Perinatal HIV Transmission Collaborative Study, 707
Ngai, A. L., 444
Ngui, S. L., 703
Nguyen, L. N., 489
Ní Challanaín, D., 16
Nicolas, L., 489
Nilsson, L., 1246
Nims, T., 795
Nisenbaum, R., 136
Noah, T. L., 638
Nødgaard, H., 474
Nolte, H., 685
Nomura, T., 441
Nooren, F. M., 1413
Norkrans, G., 434
Nugent, R., 1029
Nunoya, T., 205
Nyman, M., 1515
Obel, N., 474
Oblapenko, G., S76, S82
O'Brien, J., 975
O'Brien, T. R., 1071
O'Callahan, C. M., 1382
Odeberg, J., 938
O'Donnell, B., 1
Ogata, M., 621
Ogata, N., 511
Ogra, P. L., 497
Ohba, K.-I., 168
Ohta, M., 723
Ojoo, J. C., 975
Okamoto, H., 454
Okita, D. K., 382
Okumura, A., 505
Okwo-Bele, J.-M., S10, S16
Olano, V. A., 828
Olivé, J.-M., S37, S160, S189
Oliver, J. H., Jr., 98
Oliveria, M. J. C., S258
Olsen, J. H., 743
Olsson, T., 669
Olszewska, B., 497
Omi, S., S97, S117, S194, S268
Onderdonk, A. B., 406
O'Neill, E., 283
Onorato, I. M., 1446
Onyango, F., 57

Ooe, K., 723
Ooka, T., 38
Oon, E. S. A., S56
Oostvogel, P. M., S165
Orito, E., 168
Orle, K. A., 583
Orloff, S., 707
Orr, N., 1128
O'Shaughnessy, M. V., 801
Osterhaus, A. D. M. E., 524
O'Sullivan, M. J., 971
Otoum, H., S62, S198
Otten, M. W., Jr., S105, S122
Ottolini, M. G., 932
Ou, C.-Y., 1333
Ouma, J. H., 493
Overbaugh, J., 57
Ovesen, T., 474
Oyaizu, N., 47
Oz, H. S., 901
Pagani, J.-L., 1202
Pagano, M., 712
Pahwa, S., 47, 1029
Pahwa, S. G. for the AIDS Clinical Trials Group Protocol 190 Team, 1039
Pais, L. B., 200, 84
Palasanthiran, P., 1510
Palefsky, J. M., 927
Palin, K., 983
Palin, K. A., 989
Pallansch, M. A., S62, S71, S135, S141, S176, S198, S235, S264
Pamphlett, R., 1480
Pang, L. W., 1544
Paoletti, L. C., 1237
Papi, A., 323
Paraninfo, G., 1026
Parker, C. J., 847
Parkinson, A. J., 674
Parsonnet, J., 1240
Pass, R. F., 1080
Passaro, D. J., 992
Pastore, C., 1193
Patenaude, P., 801
Patriarca, P. A., S62, S165, S198, S228, S258
Patton, D. L., 648
Patton, L., 1324
Pauluzzi, S., 966
Pavia, A. T., 864
Paxton, W. B., 247
Pecoraro, V., 142
Pedersen, B. K., 1508
Peeling, R. W., 1153, 1453
Pemberton, L., 963
Peña-Cruz, V., 545
Peñaranda, S., S264
Pennridge Pediatric Associates, 444
Pérez, J.-L., 1087
Persidsky, Y., 1368
Persing, D. H., 98
Persson, K., 1523
Persson, M. A. A., 26
Persu, A., S241
Pesman, G. J., 191
Peter, J. B., 1302
Peterson, D. L., 1294
Peterson, P. K., 478
Petit, J.-C., 316
Petri, W. A., Jr., 734
Pezzotti, P., 775
Phair, J. P., 959
Phillips, A. N., 164, 775
Phillips, J., 959
Philpott, S. M., 992
Pialoux, G., 955
Piattelli, A., 703
Piazza, F. M., 932
Piconi, S., 1210
Pierre, L., S10
Piesman, J., 996
Pimentel-Smith, G. E., 218
Pinel, J., 1237
Pinheiro, F. P., S43
Piscitelli, S. C., 781
Pitt, J., 567, 712
Placido, R., 1531
Plichart, C., 489
Plotkin, S. A., S241
Plummer, F., 1153
Podbielski, A., 1115
Poddar, S., 214
Poelen, M. C. M., 524
Poggi, C., 1051
Poisson, L. R., 790
Poland, G. A., 678
Polis, M. A., 781
Pollmächer, T., 1284
Pollock, J. M., 1251
Polotsky, V. Y., 1159
Polyak, S. J., 1101
Polywka, S., 685
Pomeranz, S., 979
Pönkä, A., 876
Popov, V. L., 856
Popow-Kraupp, T., 32
Porta, D., S86
Portail, J. P., 716
Porter, S. R., 703
Posey, D. L., S258
Potter, J., 1
Pouliquen, J. F., 716
Poutous, A., 448
Poveda, J.-D., 955
Powderly, W., 302
Powers, D. C., 342
Pratt, R. D., 231
Prevots, D. R., S151
Price, T. H., 1184
Primi, D., 1026, 272
Prince, G. A., 932
Pritchett, L. C., 726
Probert, W. S., 400
Profizi, N., 1051
Puel, J. for SEROGEST Cohort Group, 172
Puoti, M., 272
Purcell, R. H., 511
Purvis, S. F., 947
Pybus, V., 406
Qian-Le, L., S105
Que, J. U., 871
Quick, R., 1527
Quinlivan, E. B., 1324
Quinn, T. C., 1360, 438
Quirós-Roldan, E., 272
Raab-Traub, N., 1324
Rabatić, S., 32
Rabe, L. K., 606
Rabenau, H., 1490
Raboud, J. M., 576, 801
Radebe, F., 583
Rae, S., 576, 801
Raeder, R., 1115
Raju, R., 382
Rakela, J., 448
Rakwar, J. P., 833
Ramsay, M. E., S156
Ramsey, K., 678
Ranieri, S., 255
Raoult, D., 1142
Rapier, J., 707
Rasheed, S., 1039
Rasmussen, L., 179
Rassi, A., 1272
Ray, S. C., 1360
Read, J. for National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group, 1029
Redfield, R. R., 292
Reed, G., 807
Reed, K. D., 98
Reeves, W. C., 136
Reichelderfer, P., 567
Reichler, M. R., S50, S62, S198, S205
Reijonen, H., 554
Reingold, A. L., 1025
Reingold, A. W., 992
Reiss, P., 1344, 966
Rekacewicz, C., 172
Remold, H. G., 891
Renauld-Mongénie, G., 1423
Replogle, M., 1240
Reske-Kunz, A. B., 1121
Revelo, D., 828
Reyes, M., 136
Rezza, G. for Italian Seroconversion Study, 775
Rhodes, P., S62, S198
Ricciardulli, D., 255
Rice, D. H., 726
Rich, K., 1029
Richardson, B. A., 57
Richiusa, P., 142
Ridolfi, B., S86
Rikihisa, Y., 210
Rinaldo, C., 959
Risi, J. B., Jr., S189
Rivas, F., 828
Robb, M. L., 265
Robbins, F. C., S281
Roberts, C., 16
Roberts, M. A., 1
Robertson, S. E., S235
Robin, G., 1128
Rode, C. K., 983, 989
Rodewald, A. K., 1237
Rodriguez-Barradas, M. C., 590
Rogers, A. F., 265
Roivainen, M., 554
Romani, L., 1467
Romano, J., 47
Rong-zhen, Z., S105, S122, S210
Roselli, D., 828
Rosenbaum, R. B., 633
Rosenberg, J., 992
Rosseau, S., 421
Rothstein, E. P., 444
Rouse, J. H., 1423
Rouse, M., 233
Rubens, C. E., 847
Rubin, L. G., 996
Rubinstein, A., 1206
Russell, M. W., 839
Russo, T. A., 983
Russomando, G., 1272
Ruzzante, S., 1210
Ryan, M., 1246
Sabin, C. A., 164, 775
Saglio, G., 1193
Sainte-Foie, S., 716
Saito, T., 497
Saksena, N. K., 1510
Sakurai, M., 1220
Salak-Johnson, J., 478
Salgo, M., 1039
Salisbury, D. M., S156
Sällberg, M., 1294
Salzman, M. B., 996
Sampol, J., 1142
Sanders, R., S117, S135, S141, S194, S268
Sannerud, K. J., 1087
Sapan, C. V., 283
Sartono, E., 1276
Sato, Y., S97, S117, S194, S268
Sauerbruch, T., 681
Sawyer, M., 1333
Sayers, M. H., 1259
Schaffner, A., 130
Schechter, M., 438
Schechter, M. T., 576, 801
Scheutz, F., 611, 983
Schick, H. E., 947
Schmid, D. S., 136
Schmid, S., 583
Schmidt, C., 533
Schneemann, M., 130
Schneider, I., 915
Schnur, A., S97, S117, S194

Schoedon, G., 130
Schoenbaum, E. E., 707
Schoenfeld, D., 1039
Schonkeren, J. J. M., 1413
Schoppel, K., 533
Schriefer, M. E., 466, 1432
Schröder, A., 1490
Schröter, M., 685
Schvarcz, R., 1294
Scully, C. M., 703
Seeber, A. C., 255
Seeger, W., 421
Seppälä, H., 392
Sepulveda, J., 545
Serra, C., 693
Sevall. J. S., 1302
Shafer, R. W., 561
Shankar, A. H., 151
Shanley, J. D., 309
Shapiro, D. E., 971
Sharma, C., 1134
Sharpe, S., 764
Shaw, M. M., 661
Sheikh, S., 47
Sherman, D., 179
Sherrill, L., 1080
Shibazaki, M., 1404
Shimizu, H., 1233
Shimizu, Y., 723
Shimokata, K., 723
Shinkai, M., 302
Shkurko, T. V., 1302
Shmuklarsky, M. J., 915
Sicard, D., 1198
Siitonen, A., 876
Siliciano, R. F., 1360
Simonds, R. J., 1333
Simpson, R. M., 1337
Sinangil, F., 247, 764
Singer, J., 576
Singh, N., 448
Sinicco, A., 255
Sisler, J. R., 927
Sitz, K. V., 265
Skinhoj, P., 1508
Slepon, R., 1128
Slike, B., 292
Sluijter, M., 1413
Slutsker, L., 876
Small, M. B., 1216
Smeriglio, V., 712
Smith, G., 292
Smith, J. C., S89
Smith, J. W., 482
Smith, M. A., 462
Smith, P. D., 1004
Smith, T., 921
Sobek, I., 16
Sobel, J. D., 989
Sokolow, R., 633
Sommadossi, J.-P., 1080
Sönnerborg, A., 938
Sood, S. K., 996
Soong, S.-J., 1080
Sopal, O., S173
Sorenson, J. A., 462
Sorice, S., 966
Sorrell, T. C., 414
Sottini, A., 272
Spector, S. A., 231, 302, 1080
Speight, P. M., 703
Spengler, U., 681
Spertini, F., 1202
Spinola, S. M., 1390
Spruance, S. L., 821
Srikantan, V., 63
Staege, M. S., 1121
Stagno, S., 1080
Stamm, W. E., 648, 1453
Starr, S., 1080
Stead, W. W., 1446
Steckelberg, J. M., 233
Steele, L., 136
Steigbigel, R. T., 1283
Steiger, S., 921
Steimer, K., 764
Stein, D. H., 1494
Steinhoff, M. C., 590
Stek, A. for Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group, 283
Steketee, R. W., 707
Stellini, R., 1026
Stevens, C. E., 458, 1453
Stevens, P. R., 1184
Stewart, J. A., 136
Stiehm, E. R., 283
Stites, D. P., 927
Storch, G. A., 1080
Storgaard, M., 474
Storsaeter, J., 1246
Stott, D. J., 1
Stratton, C. W., 233
Straus, S. E., 1071
Strauss, N., 979
Strebel, P. M., S241
Stricker, R., 944
Strömberg, S., 1515
Suleiman, A. J. M., S235
Sullender, W. M., 935
Summers, P. L., 756
Surowy, T. K., 458
Sutter, R. W., S1, S24, S71, S76, S82, S151, S165, S235, S241
Suzuki, H., 700
Svanborg, C., 611
Svennerholm, B., 434
Svensson, M., 611
Swanson, J. L., 373
Sweeney, Y. C., 648
Sydney Primary HIV Infection Study Group, 1502
Taffs, R. E., 441
Tai, J. Y., 364
Takada, H., 1404
Takayanagi, M., 505
Tallman, P., 989
Tamalet, C., 1051
Tanaka, T., 454
Tang, B., 1317
Tangermann, R. H., S97, S117, S194, S268, S272
Tanner, J. E., 38
Tanner, M., 921
Tao, H., 1000
Tao, J., S122
Tao, X., S105
Tarr, P. I., 726, 1382
Tatebayashi, M., 1308
Tateda, K., 205
Tauxe, R. V. for Bolivian Dysentery Study Group, 1527
Taylor, P., 38
Telfer, P., 164
Telford, S. R., III, 98
Templeton, G. L., 1446
Teo, C. G., 703
Teysseire, N., 1142
Than, S., 47
Thanh, N. T. H., 1233
Tharapel, R. A., 590
Thea, D. M., 707
Thompson, J., 807
Thompson, S. E., 1396
Thoms, M. L., S228
Thrall, R. S., 309
Thuma, P. E., 226
Thursz, M., 1093
Thwin, S. S., 606
Tibayrenc, M., 655
Tirrell, P., 678
Titus, R. G., 151
Toda, K., 1233
Tollefson, S., 807
Tolo, A., 1283
Toma, F., S241
Tomasi, M., 1004
Tomino, C., 255
Tomori, O., S10
Tompkins, L. S., 992
Tompkins, R. G., 123
Tonawanda/Williamsville Pediatrics, 1440
Toniolo, A., 693
Tool, A. T. J., 108
Tooriyama, T., 1548
Tourres, C., 1051
Townes, J. M., 1527
Trabattoni, D., 1210
Trees, D. L., 583
Tremblay, M., 176
Tsai, T., 828
Tsang, V. C. W., 486
Tsoukas, C., 176
Tsuda, F., 454
Tu, P. V., 1233
Tullson, E. D., 98
Tung, Y., 1440
Tuomanen, E., 979
Tursunova, D., S82
Twumasi, P. A., 200
Tzipori, S., 1016, 1268
Udell, I., 462
Ugen, K. E., 63
Uhlén, M., 938
Ullum, H., 1508
Upshaw, C. M., 342
Vähäsalo, P., 554
Vahey, M., 795
Valdespino, J. L., 545
Valente, F. L., S24
Valway, S., 1446
van Amerongen, G., 524
van Binnendijk, R. S., 524
van Burik, J.-A. H., 1012, 1459
VanCott, T. C., 265, 292
Van Dam, A., 1020
van Dam, G., 494
Vandenabeele, P., 108
Van Den Eynde, C., 1283
van der Ende, M. E., 966
van der Meché, F. G. A., 729
van der Meer, J. W. M., 191
van der Poll, T., 118
van Doorn, P. A., 729
van Druten, H., 191
van Gool, T., 1020
Vanham, G., 1283
van Klingeren, B., 1413
van Leeuwen, R., 1344
van Leeuwen, W. J., 1413
van Veen, A., 1413
Vaphakulov, S. H., S82
Vargas, H. E., 448
Veit, S. C. D., 265
Vella, S., 255, 966
Verastegui, M., 486
Verbrugh, H. A., 1413
Verdon, R., 1268
Verhoeven, A. J., 108
Vermeulen, M. W., 621
Vervoort, T., 1283
Verweij, C. L., 188
Vetter, J. C. M., 1020
Victor, J., 1508
Villarreal, L. I., 828
Vitale, G., 142
Vizzard, J., 1502
Vo, P. T., 330
Vo, T.-V. P., 330
Voigt, R. F., 1352
Vornhagen, R., 533
Vrtar, Z., 32
Vrtis, R., 1108
Vugia, D. J., 1432, 992
Vun, M. C., S173
Vuong, C., 1308
Vuopio-Varkila, J., 392
Wadell, G., 1523
Wagner, K. F., 265
Wahdan, M. H., S50
Wahlquist, S. P., 1527
Wainwright, R. B., 674
Wald, A., 1459

Walker, D. H., 856
Walker, M. C., 764
Walker, M. R., 1063
Walker, R. E., 781
Wallis, R., 947
Walsh, E. E., 814
Walter, R., 130
Wang, B., 1510
Wang, H.-L., 1229
Wang, L.-F., 448
Wang, S.-S., 168
Wang, X.-P., 47
Ward, H. D., 1268
Warford, A., 179
Waring, L., 992
Warren, H. S., 621
Washburn, R. G., 146, 222
Washington, J. A., 1396
Wasielewski, R., 1440
Wassef, N., 764
Wassmann, B., 1490
Watanabe, M., 1220
Waters, C. A., 790
Waters, D., 1206
Watts, D. H., 971
Webster, M., 493
Webster-Cyriaque, J., 1324
Weedon, J., 707
Wei, M. X., 38
Weigel, H. M., 966
Weiland, O., 1294
Weimer, L. E., 255
Weiner, D. B., 63
Weinmayr, B., 1020
Weiss, G., 226
Weiss, J. B., 583
Weiss, N., 921
Welch, M., 57
Wells, M., 781
Wen, B., 210
Wentworth, D. E., 7
Werner, E. R., 226
Werner, S. B., 992
Westerink, M. A. J., 84
Westerman, E. L., 856
Weverling, G. J., 966
Weyrich-Suter, C., 1202
White, C. J., 444
White, J. M., S156
Whitley, R. J., 1080
Whittam, T. S., 1382
Whittington, W. L., 1396
WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines, S215
Widjaja, K., 847
Widmer, G., 1016
Wiedermann, G., 871
Wieland-Alter, W., 697
Wiley, C. A., 1308
Wilfert, C. M., S1
Wilkinson, B. E., 342
Williams, B., 247
Williams, I. G., 703
Williams, W. V., 63
Willoughby, A., 1206
Wilson, M., 1259
Wilson, R. A., 1382
Wilson, W. R., 233
Wisniewski, H. M., 689
Wohl, D., 1324
Wolf, B. W., 218
Wolf, J., 1440
Wolitz, R., 179
Wölner-Hanssen, P., 1453
Wong, E., 1225
Wong, S., 450
Wood, P. A., 1283
Wood, R. E., 638
Woodfill, C. J. I., S30
Wormser, G. P., 210
Wright, D. J., 1206
Wright, K. E., 1548
Wright, L. C., 414
Wright, M. S., 756
Wright, P. F., 807, S247
Wu, H.-Y., 839
Wu, R.-R., 168
Xia, L., S105
Xiang, S.-H., 1510
Xing-lu, Z., S105, S122
Xu, S., 764
Yamaguchi, K., 205
Yamanishi, K., 1548
Yang, S., 1240
Yang, Z., 1446
Yarchoan, R., 1071
Yashina, T. L., 1302
Yazdanbakhsh, M., 494, 1276
Yeager, C. L., 756
Yogev, R., 1039
Yoneyama, T., 1233
Yoon, R., 966
Yoshida, H., 1233
Yoshii, K., 1233
Yoshioka, K., 505
Young, N. S., 450
Young, S. A., 352
Yu, M., 511
Yu, X.-J., 856
Yun, Z., 938
Zakrewska, J. M., 703
Zala, C., 801
Zanella, I., 1026
Zanetti, A. R., 511
Zanis, C., 674
Zanzot, E. M., 621
Zawoznik, E., 292
Zembala, M., 1531
Zhang, L., 983, 989
Zhang, L. J., 790
Zhang, Z.-X., 1294
Zhao, T. M., 1337
Zhao, W., S105
Zhi, N., 210
Zhou, J., 1255
Zhou, J. Z., 414
Zhou, S., 795
Zhou, X.-J., 1080
Ziegler, J., 1510
Zimmer, B., 1039
Zipeto, D., 179
Znoiko, O. O., 1302
Zolla-Pazner, S., 764
Zöllner, B., 685
zum Büschenfelde, K.-H. M., 1121
Zychlinsky, A., 470

Subject Index

Abortion, spontaneous, in Venezuelan equine encephalitis, 828
Abscess, liver, *Entamoeba histolytica*, cytokine responses in, gerbil model, 1176
α_1-Acid glycoprotein binding, of protease inhibitors, 1063
Acquired immunodeficiency syndrome (*See* Human immunodeficiency virus infection)
Adhesins
  Escherichia coli
    genes, epidemiology, 983
    receptor specificities, 373
  Haemophilus influenzae, lipid-binding, receptor affinity purification, 77
Adhesion molecules, in *Rickettsia conorii* infection, 1142
Adsorption enzyme immunoassay, for *Haemophilus ducreyi* antibodies, 1390
Age, vs. filariasis manifestations, 1276
AIDS (*See* Human immunodeficiency virus infection)
AIDS dementia
  cerebrospinal fluid HIV levels in, 963
  dexamethasone effects on, mouse model, 1368
Airway, epithelial cells, respiratory syncytial virus chemokine induction in, 497
Albendazole, for neurocysticercosis, serologic evolution after, 486
Alfalfa sprouts, *Salmonella* infection from, 876
Alveolar epithelial cells, lipid transfer to *Pneumocystis carinii*, 661
Alveolar macrophages, in *Candida albicans* phagocytosis, surfactant protein A in, 421
Amebiasis
  epidemiology, Bangladesh, 734
  liver, cytokine responses in, gerbil model, 1176
Ammonia, in *Gardnerella vaginalis–Prevotella bivia* symbiotic relationship, 406
Amphotericin B, liposomal, for candidiasis, 214
Animal models
  aspergillosis, in immunosuppressive therapy, mouse, 222
  Borrelia burgdorferi vaccine, mouse, 91, 400
  Borrelia meningitis, mouse, 1243
  Candida albicans infection, iron overload effects on, mouse, 1467
  Chlamydia pneumoniae infection, atherosclerosis and, mouse, 883
  Chlamydia trachomatis genital tract infection, macaque, 648
  Cryptococcus neoformans phospholipase activity, mouse, 414
  Cryptosporidium parvum infection, *Lactobacillus reuteri* effects on, mouse, 218
  cytomegalovirus replication in lung, mouse, 309
  Entamoeba histolytica liver abscess, cytokine responses in, gerbil, 1176
  enterococcal endocarditis, multidrug-resistant, rabbit, 232
  Enterococcus faecalis BM4281 endocarditis, vancomycin-resistant, rabbit, 598
  Enterocytozoon bieneusi infection, in simian immunodeficiency virus infection, rhesus monkey, 1016
  Escherichia coli O157:H7 infection
    fecal excretion in, cattle, 726
    toxins in, mouse, 611
  gram-negative sepsis, mouse, 621
  Haemophilus influenzae bronchopneumonia, mouse, 205
  hepatitis B virus mutant pathogenicity, chimpanzee, 511
  herpes simplex virus inhibition with interleukin-6 antibodies, mouse, 821
  herpes simplex virus type 2 vaccination, guinea pig, 16
  histoplasmosis, interleukin-12 in, mouse, 905
  HIV infection
    neuropathology, dexamethasone effects on, mouse, 1368
    perinatal transmission, rabbit, 1337
    vaccination for, mouse, 292
  leishmaniasis resistance, mouse, 1477
  Lyme disease, arthritogenesis and, mouse, 1000
  macrophage nitric oxide production, mouse, 1004
  malaria, cerebral, mouse, 1480
  measles vaccine, macaque, 524
  meningococcal conjugate vaccine, mouse and primates, 364
  Neisseria meningitidis serogroup C, interleukin-12–treated SCID mouse, 84
  neutropenia, anti-candidal monoclonal antibody in, mouse, 1169
  platelet response to lipopolysaccharides, mouse, 1404
  Pneumocystis carinii
    immunosuppressant effects on, rat, 901
    isoenzyme diversity, rodents, 655
  poliovirus vaccination, mouse, 441
  respiratory syncytial virus infection
    group B, immunoprophylaxis, cotton rat, 932
    maternal immunization, guinea pig, 935
  rotavirus infection
    immune responses, mouse, 1317
    immunization for, mouse, 330
  simian immunodeficiency virus infection, *Mycobacterium avium* infection in, macaque, 184
  Staphylococcus epidermidis endophthalmitis, methicillin-resistant, rabbit, 462
  streptococcal infection, C5 and C5a-ase in, mouse, 847
  streptococci, group B, vaccines, mouse, 1237
  Streptococcus gordonii endocarditis, penicillin treatment, tolerance in, rat, 70
  Streptococcus pneumoniae
    immunization, mouse, 839
    meningitis, serotype differences in, rabbit, 979
  Trypanosoma brucei brucei proliferation, interferon-γ–stimulated, mouse, 669
  tuberculosis diagnosis, cattle, 1251
  viral retinal toxicity, rabbit and pig, 1308
Anogenital cancer, condylomata acuminata and, 743
Antibiotics *(See also specific antibiotics)*
  in chemical mediator release, 1255
  prophylactic, in Lyme disease, tick attachment duration in, 996
  resistance to (*See* Resistance)
Antibody(ies) (*See also* Immunoglobulins)
  Arcanobacterium haemolyticum, 1515
  Borrelia burgdorferi, cross-reactivity in serum from nonendemic region, 466
  botulinum toxin, endogenous production, in intestinal colonization, 633
  chlamydial, pelvic inflammatory disease risk and, 1153, 1453
  cytomegalovirus, glycoprotein-specific, 533
  Encephalitozoon, in immunocompetence, Netherlands, 1020
  GB virus C E2 protein, ELISA for, 458
  in Guillain-Barre syndrome, gangliosides and *Campylobacter jejuni* cross-reactions in, 729
  Haemophilus ducreyi, enzyme immunoassays for, 1390
  hepatitis C virus
    genotypic differences in hypervariable region, 505
    variable response to, in hemodialysis unit outbreak, 26

human immunodeficiency virus
gp41 envelope glycoprotein carboxy region, vs. vertical transmission rate, 63
selection for treatment trials, 1056
vs. virus load, 231
in women, 265
human T cell lymphotropic/leukemia virus type I, vs. clinical state, 716
interleukin-6, herpes simplex virus reactivation inhibition by, 821
interleukin-12, in pulmonary histoplasmosis, mouse model, 905
islet cell, induction by enteroviruses, 554
Kaposi's sarcoma–associated herpesvirus, detection, 1071
maternal, measles vaccination with, macaque model, 524
monoclonal (*See* Monoclonal antibody[ies])
neutralizing, in HIV vaccination, 764
polioviruses, in routine vs. mass vaccination programs, Jordan, S198
rubella, vs. vaccination response, 749
Trypanosoma cruzi, long-lasting, 1272
Antibody-dependent cellular cytotoxicity, Epstein-Barr virus infection, 38
Antigen(s)
bacterial, T cell receptor activation, in HIV infection, 429
Chlamydia pneumoniae, enzyme immunoassay for, 1523
Ehrlichia chaffeensis, diversity, 856
human granulocytic ehrlichiosis, characterization, 210
Paracoccidioides brasiliensis, T cell hyporesponsiveness to, 1063
respiratory syncytial virus, in immunoprophylaxis, cotton rat model, 932
Wuchereria bancrofti, treatment effects on, 489
Antigen-presenting cells
enterobacteria-infected T cells as, in reactive arthritis, 1121
in *Leishmania major*–specific T cell priming, 151
Antiinflammatory agents, doxycycline with, for *Chlamydia trachomatis* genital infection, macaque model, 648
Antimalarial drugs, with vaccines, 871
Antiretroviral therapy (*See specific drugs, e.g.*, Zidovudine)
Aphthous ulcers, opportunistic viruses in, in HIV infection, 1324
Apolipoprotein E deficiency, atherosclerosis in, *Chlamydia pneumoniae* infection and, mouse model, 883
Apoptosis
in esophageal ulcer pathogenesis, in HIV infection, 1216
in T lymphocytes, herpes simplex virus–induced, 1220
Arcanobacterium haemolyticum infection, antibodies to, 1515
Arthritis
in Lyme disease, mouse model, 1000
reactive, in enterobacterial infection, T cell subsets in, 1121
Aspergillosis
epidemiology, in bone marrow transplantation, 1459
in immunosuppressive therapy, mouse model, 222
Aspergillus fumigatus
infection, granulocyte colony-stimulating factor for, 1012
pneumocyte binding, 146
Asthma
exacerbation, rhinovirus-induced interleukin-8 in, 323
respiratory syncytial virus bronchiolitis relation to, 32
Astrocytes, chemokine response, 478
Atherosclerosis, *Chlamydia pneumoniae* infection and, mouse model, 883
Atovaquone, for malaria, 1544
Avidity index, immunoglobulin G, in cytomegalovirus infection diagnosis, in pregnancy, 944

B cells
cytomegalovirus effects on, 533
hepatitis B virus core protein mutations in, 1093
in *Leishmania major*–specific T cell priming, 151
in respiratory syncytial virus bronchiolitis, 32
Babesiosis
epidemiology, 1432
transfusion-transmitted, 1259
Bacille Calmette-Güerin vaccination, in poliomyelitis eradication, S268
Bacteremia
Escherichia coli, adhesin genes in, epidemiology, 983
Streptococcus pneumoniae, prevention with intranasal immunization, mouse model, 839
Bacterial vaginosis, microorganism symbiotic relationship in, 406
Bactericidal/permeability-increasing protein, release in blood, ex vivo studies, 108
*Bam*HI A rightward open-reading frame-1 protein, Epstein-Barr virus, antibody response to, 38
BARF1 protein, Epstein-Barr virus, antibody response to, 38
Basophils, activation, respiratory syncytial virus in, 497
Benznidazole, for Chagas' disease, long-lasting antibody detection, 1272
Beta cell antibodies, induction by enteroviruses, 554
Biliary epithelial cells, *Cryptosporidium parvum* infection, in vitro model, 1268
Birth weight, vs. maternal vaginal *Escherichia coli* colonization, 606
Black-pigmented bacteria, lipopolysaccharides from, platelet response to, mouse model, 1404
Blood transfusion, babesiosis transmission in, 1259
Bone marrow transplantation
aspergillosis in, 1459
cytomegalovirus infection in, 1490
Bordetella pertussis infection
helper T cell activation in, 1246
vaccination, immunodominant domains in, 1423
Borrelia, newly identified, meningitis, mouse model, 1243
Borrelia burgdorferi infection (*See also* Lyme disease)
cross-reactivity, in nonendemic region, 466
epidemiology, Sweden, 720
genetic heterogeneity, United States, 98
vaccines, mouse model, 91, 400
Botulism, from intestinal colonization, in Crohn's disease, 633
Boutonneuse fever, *Rickettsia conorii*, cytokine secretion in, 142
BOX primers, in polymerase chain reaction, persistent *Streptococcus pneumoniae* carrier detection, 590
Brain
injury, chemokine response in, 478
lymphoma, human herpesvirus type 8 in, 1193
malaria
iron chelation therapy for, nitric oxide formation and, 226
mouse model, 1480
Taenia solium infection, treatment, serologic evolution after, 486
Breast cancer, condylomata acuminata and, 743
Bronchiolitis, respiratory syncytial virus, CD23 B cell increase in, 32
Bronchoalveolar lavage, in cystic fibrosis, cytokine detection in, 638
Bronchopneumonia, *Haemophilus influenzae*, mouse model, 205
Brugia malayi infection, cytokine measurement in, factors affecting, 1276

C5 and C5a-ase (complement system), in group B streptococcal infection, mouse model, 847
CagA protein, *Helicobacter pylori*, seroprevalence in healthy persons, 1240
Campylobacter jejuni, cross-reactive with gangliosides, in Guillain-Barre syndrome, 729
Cancer, condylomata acuminata and, 743
Candida albicans
antigen, T cell receptor activation, in HIV infection, 429
infection, iron overload in, T helper cell response in, mouse

model, 1467
monoclonal antibodies to, in neutropenia, mouse model, 1169
phagocytosis, surfactant protein A in, 421
Candidiasis
granulocyte colony-stimulating factor for, 1012
liposomal amphotericin B for, 214
$CAP18_{106-138}$-immunoglobulin G conjugate, for endotoxin neutralization, mouse model, 621
Cardiomyopathy, dilated, coxsackievirus group B infection in, 693
Carriers
human T cell lymphotropic/leukemia virus type I, antibodies in, 716
Streptococcus pneumoniae
in HIV infection, 590
prevention with intranasal immunization, mouse model, 839
Castleman's disease, HIV infection with, Kaposi's sarcoma herpesvirus DNA load in, 1198
CD23 antigen, on B cells, in respiratory syncytial virus bronchiolitis, 32
CD4 antigen, on T cells (*See* T cells, CD4)
Ceftriaxone, in chemical mediator release, 1255
Cellular immune response (*See also* B cells; T cell[s])
Bordetella pertussis infection, 1246
enterobacteria-infected T cells, in reactive arthritis, 1121
HIV exposure without seroconversion, 272
HIV infection, in pentoxifylline therapy, 1210
influenza vaccination, 342
paracoccidioidomycosis, 1263
Central nervous system, lymphoma, human herpesvirus type 8 in, 1193
Cerebral malaria
iron chelation therapy for, nitric oxide formation and, 226
mouse model, 1480
Cerebrospinal fluid
cytokines in, in subacute sclerosing panencephalitis, 689
HIV DNA in, antiretroviral agent effects on, 434
HIV RNA in, vs. AIDS dementia stage, 963
Cervix
intraepithelial neoplasia
condylomata acuminata and, 743
human papillomavirus in, cytotoxic T cell response to viral proteins, 927
secretions from, HIV-specific IgA in, 265
CGP 61755 protease inhibitor, for HIV infection, glycoprotein binding in, 1063
Chagas' disease, long-lasting antibodies in, 1272
Chancroid
antibodies in, enzyme immunoassays for, 1390
diagnosis, clinical vs. laboratory, 583
Chemokines
brain cell response to, 478
respiratory syncytial virus induction, in airway epithelial cells, 497
Chemotactic activity, middle ear effusions, 474
Chickenpox, vaccines, dose titration study, 444
Children (*See* Pediatric patients)
Chlamydia pneumoniae infection
atherosclerosis and, mouse model, 883
respiratory, rapid diagnosis, 1523
Chlamydia trachomatis infection
antibodies in, pelvic inflammatory disease risk and, 1153, 1453
genital tract, treatment, macaque model, 648
Chlamydial infection, repeat, epidemiology, 1519
Chloroquine, with vaccines, 871
Cholera
O1 El Tor strain, molecular characterization, in Calcutta, India, 1134
vaccination, with antimalarial drugs and other vaccines, 871
Cholera toxin B, in HIV intranasal immunization, mouse model, 292
Chorioretinitis, *Toxoplasma gondii*, from contaminated food, 1280
Chronic fatigue syndrome, immune response in, 136
Cidofovir, resistance to, cytomegalovirus, 1087
Ciprofloxacin, resistance to, *Neisseria gonorrhoeae*, 1396
Circadian rhythms, septic shock, 1283
Circulating filarial antigen, treatment effects on, 489
Clinical trials
HIV infection
plasma RNA level as outcome, 576
surrogate marker evaluation for, perspective, 237
Clostridium botulinum, colonization, in Crohn's disease, 633
Colonization
Clostridium botulinum, in Crohn's disease, 633
Escherichia coli, vaginal, perinatal complications from, 606
nasopharyngeal, otitis media and, 1440
Streptococcus pneumoniae, in HIV infection, 590
Colony-stimulating factors, in *Mycobacterium avium* infection, in vitro model, 891
Complement system, C5 and C5a-ase, in group B streptococcal infection, mouse model, 847
Condylomata acuminata, cancer and, 743
Congenital disorders, cytomegalovirus infection, ganciclovir for, 1080
Conidia, *Aspergillus fumigatus*, pneumocyte binding, 146
Coxsackieviruses
group B
receptors, 697
vascular endothelial cell infection, 693
islet cell antibody induction by, 554
Crohn's disease, *Clostridium botulinum* colonization in, 633
Cryptococcus neoformans, virulence factors, phospholipase activity as, mouse model, 414
Cryptosporidium parvum infection
biliary epithelial cells, in vitro model, 1268
Lactobacillus reuteri effects on, mouse model, 218
CTX elements, *Vibrio cholerae* O1 El Tor strains, 1134
Culture
bacterial vaginosis organisms, symbiotic relationship evidence in, 406
chlamydial, 1523
Cryptococcus neoformans, phospholipase activity in, 414
human granulocytic ehrlichiosis agent, 210
human immunodeficiency virus, in vertical transmission timing, 712
interleukin-4–treated macrophages, 130
leukocyte, in cytomegalovirus infection prediction, in HIV infection, 302
poliovirus, S43
in global laboratory network, S113
CVD103-HgR (cholera) vaccine, with antimalarial drugs and other vaccines, 871
Cyclosporin A, immunosuppression, aspergillosis, mouse model, 222
Cystic fibrosis, cytokine production in, 638
Cysticercosis, treatment, serologic evolution after, 486
Cystitis, *Escherichia coli*, adhesin genes in, epidemiology, 983
Cytokines (*See also specific cytokines*)
antiinflammatory, in sepsis, 118
cerebrospinal fluid, in subacute sclerosing panencephalitis, 689
production
autologous platelet interaction in, 123
in *Bordetella pertussis* infection, 1246
in *Brugia malayi* infection, factors affecting, 1276
in chronic fatigue syndrome, 136
in cystic fibrosis, 638
in hepatitis C, 681
in HIV infection, vs. disease progression, 47

in *Leishmania major*–specific T cells, 151
in leishmaniasis, diffuse vs. localized forms, 737
in *Mycobacterium avium* infection, in vitro model, 891
pyrogenic, in fever of unknown origin, 191
Cytomegalovirus
humoral immune response to, glycoprotein-specific antibody synthesis in, 533
infection
antiviral susceptibility testing in, in immunodeficiency, 1087
congenital, ganciclovir for, 1080
drug resistance in, 1087
in HIV infection
genotypes, 179
risk evaluation, 302
monitoring for, in bone marrow transplantation, 1490
retinal toxicity in, rabbit and pig models, 1308
replication, mouse model, 309
in transplantation, genotypes, 179

DAB_{389}IL-2 (interleukin-2 fusion protein), HIV inhibition by, in peripheral blood mononuclear cell culture, 790
ddI (*See* Didanosine)
Deferoxamine, in iron overload, in *Candida albicans* infection, mouse model, 1467
Dementia, AIDS
cerebrospinal fluid HIV levels in, 963
dexamethasone effects on, mouse model, 1368
Dendritic cells, in *Leishmania major*–specific T cell priming, 151
Dengue virus, progenitor cell inhibition by, in vitro model, 1497
Desferrioxamine B, for cerebral malaria, nitric oxide formation and, 226
Deuterium, in polio vaccine stabilization, S4, S247
Dexamethasone
for HIV infection, neuropathology effects, mouse model, 1368
for *Pneumocystis carinii* suppression, rat model, 901
for *Staphylococcus epidermidis* endophthalmitis, methicillin-resistant, rabbit model, 462
Diabetes mellitus, insulin-dependent, induction by enteroviruses, 554
Diarrhea
bloody, etiology and treatment, in Bolivia, 1527
Enterocytozoon bieneusi, in simian immunodeficiency virus infection, rhesus monkey model, 1016
Escherichia coli, enteropathogenic, characterization, Seattle, 1382
polio vaccine effects, Brazil, S258
rotavirus, immune responses in, mouse model, 1317
Shigella, immunoglobulin G subclass response in, 1128
Didanosine, for HIV infection, 1344
cerebrospinal fluid viral DNA levels and, 434
hydroxyurea with, 801
lamivudine and zidovudine with, 1051
virus susceptibility to, 561
vs. zidovudine, 255
Diethylcarbamazine, ivermectin with, for *Wuchereria bancrofti* infection, 489
Dihydropteroate synthase polymorphisms, in *Pneumocystis carinii*, 482
Diphtheria–tetanus toxoid–pertussis, vaccination, in poliomyelitis eradication program, S268
Disabled infectious single cycle viruses, herpes simplex virus type 2, vaccination with, 16
Disseminated intravascular coagulation, platelet-monocyte interactions in, cytokine production and, 123
DNA analysis
in cytomegalovirus susceptibility testing, 1087
HIV, in pregnancy, 57
random amplified polymorphic, group A streptococci T1M1 serotype identification, 392
Shigella sonnei, 864
Streptococcus pyogenes, 723
T cell apoptosis, herpes simplex virus–induced, 1220
DNA vaccines, *Borrelia burgdorferi*, mouse model, 91
Doxycycline, for *Chlamydia trachomatis* genital infection, macaque model, 648
Drug abuse
hepatitis A risk in, 1225
HIV transmission in, 1206
Drug resistance (*See* Resistance)
Dysentery
epidemiology, Bangladesh, 734
Shigella
immunoglobulin G subclass response in, 1128
macrophage apoptosis induction in, 470

E2 protein, GB virus C, antibodies to, ELISA for, 458
Ear, middle, effusion in, interleukin-8 in, 474
Ehrlichia chaffeensis, antigenic diversity, 856
Ehrlichiosis
agent characterization, 210
epidemiology, 720, 1432
Elastase, release in blood, ex vivo studies, 108
Elderly persons, hepatitis B vaccination with yeast recombinant vaccine, 1494
Electrophoresis, pulsed-field gel, in *Shigella sonnei* characterization, 864
ELISA (*See* Enzyme-linked immunosorbent assay)
Emulsomes, in HIV intranasal immunization, mouse model, 292
Encephalitis
in HIV infection, dexamethasone effects on, mouse model, 1368
subacute sclerosing, cerebrospinal fluid cytokines in, 689
Venezuelan equine, epidemiology, Colombia, 828
Encephalitozoon infection, epidemiology, Netherlands, 1020
Endocarditis
enterococcal, multiresistant, rabbit model, 232
Enterococcus faecalis BM4281, vancomycin-resistant, rabbit model, 598
Streptococcus gordonii, penicillin for, tolerance in, 70
Endophthalmitis, methicillin-resistant *Staphylococcus epidermidis*, intravitreal treatment, rabbit model, 462
Endothelial cells
chemical mediator release from, antibiotic-induced, 1255
Rickettsia conorii adherence to, 1142
vascular, coxsackievirus group B infection, 693
Endotoxemia, experimental, interleukin measurement in, 118
Endotoxin (*See* Lipopolysaccharide)
Entamoeba dispar, epidemiology, Bangladesh, 734
Entamoeba histolytica
epidemiology, Bangladesh, 734
liver abscess, cytokine responses in, gerbil model, 1176
Enterobacteria, in T cells, in reactive arthritis, 1121
Enterobacteriaceae, lipopolysaccharides from, platelet response to, mouse model, 1404
Enterococci, endocarditis, multiresistant, rabbit model, 232
Enterococcus faecalis BM4281 endocarditis mutants, vancomycin-resistant, rabbit model, 598
Enterocytozoon bieneusi infection, in simian immunodeficiency virus infection, rhesus monkey model, 1016
Enterotoxin, *Escherichia coli*, as influenza vaccine adjuvant, 352
Enteroviruses, islet cell antibody induction by, 554
Enzyme immunoassay
for chlamydial infection, 1523
for *Haemophilus ducreyi* antibodies, 1390
for measles, immunoglobulin M capture, 195
Enzyme-linked immunosorbent assay

for *Borrelia burgdorferi*, antibodies cross-reacting with, 466
for chlamydial hsp60 antibodies, 1153
for GB virus C antibody, 458
for Kaposi's sarcoma–associated herpesvirus, 1071
for *Loa loa*–specific immunoglobulin subclasses, 158
for *Mycobacterium avium* complex interaction with mannose-binding protein, 1159
for polio vaccine response, S264
Eosinophil(s), activation, respiratory syncytial virus in, 497
Eosinophilia, in HIV infection, 1283
Epidemiology
aspergillosis, in bone marrow transplantation, 1459
babesiosis, 1432
Borrelia burgdorferi
cross-reacting antibodies, Papua New Guinea, 466
genetic heterogeneity, United States, 98
Sweden, 720
Chlamydia trachomatis antibodies, in pelvic inflammatory disease, 1453
chlamydial infection repeat cases, 1519
Ehrlichia, Sweden, 720
Ehrlichia chaffeensis strains, Oklahoma, 856
ehrlichiosis, California, 1432
Encephalitozoon infection, in immunocompetence, Netherlands, 1020
Entamoeba infection, Bangladesh, 734
Escherichia coli
adhesin genes, 983
enteropathogenic, Seattle, 1382
GB virus C infection (hepatitis G), 168, 1229, 450, 454
gonorrhea repeat cases, San Francisco, 1519
Guillain-Barre syndrome, Latin America, S160
Haemophilus ducreyi infection, antibody assays in, 1390
Helicobacter pylori CagA protein, in healthy persons, 1240
hepatitis A, in homosexual and bisexual populations, 1225
hepatitis C virus
genotypes, age factors in, 685
in hemodialysis unit, 26
hepatitis G (*See* Epidemiology, GB virus C infection)
human granulocytic ehrlichiosis, Sweden, 720
human immunodeficiency virus infection, with Castleman's disease, Kaposi's sarcoma–associated herpesvirus DNA load in, 1198
Lyme disease, 1432, 720
malaria, after vaccination, Tanzania, 921
Mexico virus, United Kingdom, 951
parainfluenza virus infection, in pediatric patients, 807
poliomyelitis (*See* Poliomyelitis, epidemiology)
Salmonella infection, from alfalfa sprouts, 876
Serratia marcescens wound infection, California, 992
Shigella sonnei, Utah, 864
streptococci, group A, TiMi serotype, Finland, 392
Streptococcus pneumoniae penicillin resistance, Netherlands, 1413
tickborne diseases, California, 1432
toxoplasmosis, foodborne, Korea, 1280
tuberculosis, 1535
urethritis, East African men, 833
Venezuelan equine encephalitis, Colombia, 828
Vibrio cholerae O1 El Tor, Calcutta, India, 1134
Epithelial cells
airway, chemokine induction by respiratory syncytial virus, 497
alveolar, lipid transfer to *Pneumocystis carinii*, 661
biliary, *Cryptosporidium parvum* infection, in vitro model, 1268
Histoplasma capsulatum infection, yeast cell wall alterations in, 1538
Epstein-Barr virus
infection, antibody-dependent cellular cytotoxicity in, 38
in Kaposi's sarcoma lesions, Uganda, 947
in oral lesions, in HIV infection, 1324
Equine encephalitis, Venezuelan, epidemiology, Colombia, 828
Errata
de Kleijn et al., 1997;175:191–5, 1027
Gulati et al., 1996;174:1223–37, 1027
Xu et al., 1996;1974:1127–30, 1027
ESAT-6 antigen detection, in tuberculosis diagnosis, cattle model, 1251
Escherichia coli
heat-labile enterotoxin from, as influenza vaccine adjuvant, 352
infection
antibiotics for, mechanisms, 1255
enteropathogenic, characterization, Seattle, 1382
septic shock in, circadian time structure, 1283
urinary tract, sexual transmission, 989
lipopolysaccharide from, platelet response to, mouse model, 1404
uropathogenic
adhesin genes in, epidemiology, 983
PapG adhesins, receptor specificities, 373
vaginal colonization, perinatal complications from, 606
Escherichia coli O157:H7
fecal excretion, cattle, 726
toxins, mouse model, 611
E-selectin, expression, in *Rickettsia conorii* infection, 1142
Esophageal ulcers, in HIV infection, pathogenesis, 1216

Fatigue, chronic, immune response in, 136
Fever of unknown origin
interleukin-1 receptor antagonist in, 191
pyrogenic cytokines in, 191
Fibrinogen, in group A streptococci plasmin-like activity acquisition, 1115
Filamentous hemagglutinin, in *Bordetella pertussis* vaccine, 1423
Filariasis
brugian, cytokine measurement in, factors affecting, 1276
Loa loa, immunoglobulin G subclasses and, 158
Wuchereria bancrofti, circulating antigen of, treatment effects on, 489
FK506 (tacrolimus)
immunosuppression, in aspergillosis, mouse model, 222
in *Pneumocystis carinii* suppression, rat model, 901
Fluoroquinolones, resistance to, *Neisseria gonorrhoeae*, 1396
Foodborne diseases
Salmonella infection, from alfalfa sprouts, 876
toxoplasmosis, epidemiology, Korea, 1280
c-fos gene product, expression, in cerebral malaria, mouse model, 1480
Foscarnet, susceptibility testing, in cytomegalovirus infection, 1087
Fungal infection, treatment with granulocyte colony-stimulating factor, 1012

Ganciclovir, for cytomegalovirus infection
congenital, 1080
resistance to, 1087
Gangliosides, antibodies to, cross-reactive with *Campylobacter jejuni*, in Guillain-Barre syndrome, 729
Gardnerella vaginalis, *Prevotella bivia* symbiotic relationship with, in bacterial vaginosis, 406
Gastroenteritis, Mexico virus, epidemiology, United Kingdom, 951
GB virus C infection (hepatitis G)
acute, viral RNA detection in, 1302
E2 protein, antibodies to, detection with ELISA, 458
epidemiology, 168, 450, 454, 1229
genotyping, China, 1229

transmission, in HIV infection, 1025
Gel electrophoresis, pulsed-field, in *Shigella sonnei* characterization, 864
Gel shift analysis, hepatitis C virus quasispecies heterogeneity, interferon response and, 1101
Genetically inactivated herpes simplex virus type 2, vaccination with, 16
Genital tract
cancer, condylomata acuminata and, 743
Chlamydia trachomatis infection, treatment, macaque model, 648
herpes simplex infection, vaccination, guinea pig model for, 16
ulcers, diagnosis, clinical vs. laboratory, HIV infection and, 583
Genomic macrorestriction analysis, *Borrelia burgdorferi*, 98
Gentamicin, for *Enterococcus faecalis* BM4281 endocarditis, rabbit model, 598
Geriatric patients, hepatitis B vaccination with yeast recombinant vaccine, 1494
Glial cells, chemokine response, 478
Glucose phosphate isomerase, *Pneumocystis carinii*, diversity, rodent models, 655
Glycopeptides, resistance, *Enterococcus faecalis* BM4281, rabbit model, 598
Glycoproteins
cytomegalovirus antibodies specific to, 533
herpes simplex virus type 2, depletion for vaccine preparation, 16
Paracoccidioides brasiliensis, T cell hyporesponsiveness to, 1063
protease inhibitor binding, 1063
Gonorrhea
drug resistance in, 1396
in pelvic inflammatory disease, 1153, 1453
repeat cases, epidemiology, 1519
gp41, HIV, transmembrane envelope glycoprotein carboxy region, antibody
gp160, HIV, intranasal immunization with, mouse model, 292
response to, vs. vertical transmission rate, 63
Gram-negative organisms, $CAP18_{106-138}$-immunoglobulin G conjugate action on, mouse model, 621
Granulocyte colony-stimulating factor
for fungal infection, 1012
for *Mycobacterium avium* infection, in vitro model, 891
neutrophil oxidative function effects, 1184
Granulocyte-macrophage colony-stimulating factor, for *Mycobacterium avium* infection, in vitro model, 891
Granulocytic ehrlichiosis
agent characterization, 210
epidemiology, Sweden, 720
Growth-related peptide-α, respiratory syncytial virus induction, in airway epithelial cells, 497
Guillain-Barré syndrome
vs. botulism from intestinal colonization, in Crohn's disease, 633
cross-reactive antibodies in, gangliosides and *Campylobacter jejuni*, 729
epidemiology, Latin America, S160
mortality and morbidity assessment, implications for acute flaccid paralysis surveillance in, S151

Haemophilus ducreyi infection
antibodies in, enzyme immunoassays for, 1390
diagnosis, clinical vs. laboratory, 583
Haemophilus influenzae
bronchopneumonia, mouse model, 205
colonization, otitis media and, 1440
lipid-binding adhesin, receptor affinity purification, 77
Hairy leukoplakia, opportunistic viruses in, in HIV infection, 1324
Health care workers, influenza vaccination, reduced mortality in elderly patients, 1
Heart, coxsackievirus group B infection, 693
Heat shock proteins, chlamydial, antibodies to, pelvic inflammatory disease risk and, 1153, 1453
Helicobacter pylori, CagA protein–positive, seroprevalence in healthy persons, California, 1240
Hemagglutinin
filamentous, in *Bordetella pertussis* vaccine, 1423
influenza A virus, vaccination with, 342
in uropathic *Escherichia coli* adhesin receptor specificity assessment, 373
Hemagglutinin-neuraminidase gene, mumps virus, Urabe vaccine strain, 1548
Hemodialysis, hepatitis C virus epidemiology in, 26
Hemolytic uremic syndrome, in *Escherichia coli* O157:H7 infection, mouse model, 611
Hemophilia
GB virus C infection in, molecular investigation, Japan, 454
HIV infection in, hepatitis C genotype and, 164
Hemorrhagic fever, dengue, progenitor cell inhibition in, in vitro model, 1497
Hepatitis A, epidemiology, in homosexual and bisexual populations, 1225
Hepatitis B, vaccination
mutation emergence in, chimpanzee model, 511
nonresponders, 678
with yeast recombinant vaccine, in elderly persons, 1494
Yupik Eskimos, 674
Hepatitis B virus
core protein mutations in, disease progression and, 1093
genotyping, 1285
geographic origins, 1285
mutant, pathogenicity, chimpanzee model, 511
variants, 1285
Hepatitis C
hepatitis G with, 1302
in HIV infection, transmission, 1025
interferon-α for, 1294
intrahepatic cytokine production in, 681
partial seroreversion in, 316
Hepatitis C virus
genotypes
age factors in, 685
vs. HIV infection progression, 164
in liver transplantation candidates, 448
hypervariable region, humoral immune response to
genotypic differences, 505
in hemodialysis unit outbreak, 26
quasispecies heterogeneity, interferon response and, 1101
variation, in immunodeficiency, 938
Hepatitis G (GB virus C infection)
acute, viral RNA detection in, 1302
E2 protein, antibodies to, detection with ELISA, 458
epidemiology, 168, 450, 454, 1229
hepatitis C with, 1302
transmission, in HIV infection, 1025
Herpes simplex virus
infection
genital, clinical vs. laboratory diagnosis, 583
retinal toxicity in, rabbit and pig models, 1308
inhibition with interleukin-6 antibodies, mouse model, 821
T cell apoptosis in, 1220
type 2, vaccination, with genetically inactivated virus, 16
Histamine-forming enzyme, formation, in platelet response to lipopolysaccharide, mouse model, 1404
Histoplasma capsulatum, cell wall alterations in, during cellular

infection, 1538
Histoplasmosis
Paracoccidioides brasiliensis antigen response after, 1063
pulmonary, interleukin-12 in, mouse model, 905
HIV infection (*See* Human immunodeficiency virus infection)
Homosexual population, hepatitis A risk in, 1225
Human granulocytic ehrlichiosis
agent characterization, 210
epidemiology, 720, 1432
Human herpesvirus type 8 (Kaposi's sarcoma–associated herpesvirus)
antibodies to, detection, 1071
in HIV infection
with Castleman's disease, 1198
in oral lesions, 1324
variants, 703
in Kaposi's sarcoma lesions, Uganda, 947
in lymphoma, 1193
variants, 703
Human immunodeficiency virus type 1
antibodies to, selection for treatment trials, 1056
burden, in early stage, in women, 795
in cerebrospinal fluid, vs. AIDS dementia stage, 963
culture, in vertical transmission timing, 712
detection, perinatal, 707
drug susceptibility testing, 561
exposure to, T cell repertoires in, 272
infectious, measurement, 247
inhibition, by interleukin-2 fusion protein (DAB_{389}IL-2), in peripheral blood mononuclear cell culture, 790
plasma RNA measurement, in treatment evaluation, 576
replication, 561
reverse transcriptase mutations in, drug susceptibility testing, 561
RNA
in cerebrospinal fluid
vs. AIDS dementia stage, 963
antiretroviral agent effects on, 434
detection, perinatal, 707
in maternal-infant transmission, 1206
measurement, 247
vs. mortality risk, 1029
in treatment evaluation, 576
Human immunodeficiency virus type 1 infection
advanced, treatment, 1344
asymptomatic
pentoxifylline for, 1210
polyclonal T cell response in, 1360
Castleman's disease with, Kaposi's sarcoma herpesvirus DNA load in, 1198
CD4 T cells in
vs. exposure without seroconversion, 272
interleukin-2 effects on, 781
vs. mortality risk, 1029
vs. quantitative measures, 247
vs. rate of decline in, 775
as surrogate marker, 237, 576
combination drug therapy for, 1051, 1344
Cryptosporidium parvum infection in, *Lactobacilli reuteri* effects on, mouse model, 218
cytokine production in, 1507
cytomegalovirus infection in
genotypes, 179
risk evaluation, 302
diagnosis
perinatal, 707
before seroconversion, outcome in, 959
didanosine for, 1344
cerebrospinal fluid viral DNA levels and, 434
hydroxyurea with, 801
vs. zidovudine, 255
drug-resistant, transmission, 1502
early, detection, outcome in, 959
Enterocytozoon bieneusi derived from, transmission to monkeys, 1016
eosinophilia in, 1283
esophageal ulcer pathogenesis, 1216
GB virus C transmission in, 1025
hepatitis C in
genotypic effects, 164
seroreversion, 316
transmission, 1025
variants, 938
human herpesvirus type 8 variants in oral tissues, 703
human T lymphotropic virus type I infection with, HIV replication rate in, 438
hydroxyurea and didanosine for, 801
immunity to, 272
interleukin-1β production in, 1507
interleukin-2 for, 781
Kaposi's sarcoma in (*See* Human herpesvirus type 8; Kaposi's sarcoma)
long-term nonprogressing
polyclonal T cell response in, 1360
viral characterization in, 1510
lymphoma in, human herpesvirus type 8 in, 1193
mildly symptomatic, treatment, 255
Mycobacterium avium infection in, cytokine effects on, in vitro model, 891
neuropathology in, dexamethasone effects on, mouse model, 1368
nevirapine for, high-dose, 966
nonprogressing
polyclonal T cell response in, 1360
viral characterization in, 1510
oral lesions in, opportunistic viruses in, 1324
in pediatric patients (*See* Pediatric patients, HIV infection in)
perinatal, diagnosis, 1333
persons at high risk for, T cell repertoires in, vs. HIV-positive persons, 272
pneumococcal vaccination in, 975
polyclonal T cell response in, without clinical progression, 1360
in pregnancy (*See also* Human immunodeficiency virus infection, transmission, vertical)
anti-HIV immunoglobulin for, 283
gp41 envelope glycoprotein carboxy region antibody response in, 63
viral shedding in, factors affecting, 57
virus load in, 172
primary
autologous neutralizing antibody in, vs. virus load, 231
rapid progression without seroconversion, 1352
treatment, 1051
progression
vs. cytokine pattern, in pediatric patients, 47
polyclonal T cell response and, 1360
in seronegativity, 955
without seroconversion, 1352
protease inhibitors for, glycoprotein binding in, 1063
quantitative virologic measures in, 247
ribavirin for, virus drug sensitivity after, 176
seroconversion in absence of, 272, 1352

CD4 lymphocyte decline after, 775
diagnosis before, outcome in, 959
seronegative, with AIDS symptoms, 955
in simian immunodeficiency virus infection, *Mycobacterium avium* infection in, 184
Streptococcus pneumoniae colonization in, 590
surrogate markers for, perspective, 237
T cell repertoires in (*See also* Human immunodeficiency virus infection, CD4 T cells in)
vs. seronegative, high-risk persons, 272
T cell receptor subsets in, bacterial antigen activation, 429
transmission
drug-resistant, 1502
with genital ulcers, 583
vertical
antibody response to gp41 envelope glycoprotein carboxy region, 63
anti-HIV immunoglobulin protection against, 283
factors affecting, 57
long-term nonprogressing type, 1510
vs. maternal virus load, 172
prevention, 971
rabbit model, 1337
risk factors for, 567
timing, 712
variables in, 1206
treatment (*See also specific drugs*)
in advanced disease, 1344
with combination drug therapy, 1051
monitoring by lymph node aspiration, 1202
plasma RNA levels in, 576
tuberculosis in, virus-bacterial potentiation in, in vitro model, 1531
tumor necrosis factor-α in, 1507
promoter region polymorphisms in, 188
vaccination for
mouse model, 292
neutralization activity studies in, 764
virus burden in, in early stage, in women, 795
in women, mucosal immune responses in, 265
zalcitabine for, 1344
zidovudine for, 1344
cerebrospinal fluid viral DNA levels and, 434
vs. didanosine, 255
efficacy, quantitative virologic measures for, 247
Human monocytic ehrlichiosis
antigenic diversity, 856
epidemiology, 1432
Human papillomavirus, proteins, cytotoxic T cell response to, cervical intraepithelial neoplasia and, 927
Human T cell lymphotropic/leukemia virus type I
antibodies to, vs. clinical state, 716
HIV infection with, 438
Humoral immune response (*See also* Antibody[ies]; Immunoglobulin[s])
Arcanobacterium haemolyticum infection, 1515
cytomegalovirus, glycoprotein-specific antibody synthesis in, 533
hepatitis C virus hypervariable region, genotypic differences, 505
influenza vaccination, 342
iron overload, in *Candida albicans* infection, mouse model, 1467
poliomyelitis vaccine, oral with inactivated virus, S215, S228
rotavirus infection, mouse model, 1317
Hydroxyurea, for HIV infection, didanosine with, 801
Hyperimmune anti-HIV immunoglobulin, in pregnancy, 283
Hypervariable region, hepatitis C virus
antibody response to, in hemodialysis unit, 26
humoral immune response to, genotypic differences, 505
variation in immunodeficiency, 938

Ibuprofen, doxycycline with, for *Chlamydia trachomatis* genital infection, macaque model, 648
Imipenem, in chemical mediator release, 1255
Immune complex dissociation, p24 antigen detection after, perinatal, 1333
Immune response
cellular (*See* Cellular immune response)
in chronic fatigue syndrome, 136
hepatitis B vaccine, in older persons, 1494
heterotypic, in rotavirus immunization, mouse model, 330
humoral (*See* Humoral immune response)
mucosal
in HIV infection, in women, 265
in HIV intranasal immunization, mouse model, 292
Neisseria meningitidis serogroup C, in interleukin-12–treated SCID mouse, 84
polio vaccination
evaluation, S264
in routine vs. mass vaccination programs, Jordan, S198
rubella vaccination, 749
vaccinia vaccines, vs. administration route, 756
Immunization (*See* Vaccination)
Immunoblot assay, for neurocysticercosis, 486
Immunodeficiency (*See also* Human immunodeficiency virus infection)
Cryptosporidium parvum infection in
Lactobacilli reuteri effects on, mouse model, 218
in vitro model, 1268
cytomegalovirus genotypes in, in transplantation, 179
cytomegalovirus infection in, antiviral susceptibility testing in, 1087
cytomegalovirus replication in, mouse model, 309
hepatitis C virus variation in, 938
Immunoglobulin(s) (*See also* Antibody[ies])
intravenous
anti-HIV, in pregnancy, 283
in streptococcal group B infection, mouse model, 1237
Immunoglobulin A
anti-gp160, induction in intranasal immunization, mouse model, 292
HIV-specific, in women, 265
Immunoglobulin E
production, after *Schistosoma mansoni* treatment, 493
respiratory syncytial virus–specific, in bronchiolitis, 32
Immunoglobulin G
anti-gp160, induction in intranasal immunization, mouse model, 292
peptide conjugate, for endotoxin neutralization, mouse model, 621
subclasses
in *Loa loa* infection, 158
in *Shigella* infection, 1128
Immunoglobulin G4
production, after *Schistosoma mansoni* treatment, 493
respiratory syncytial virus–specific, in bronchiolitis, 32
Immunoglobulin G avidity index, in cytomegalovirus infection diagnosis, in pregnancy, 944
Immunoglobulin M capture enzyme immunoassay
for measles diagnosis, 195
for polio vaccine response, S264
Immunomodulation
in HIV infection, interleukin-2 in, 781
iron chelation therapy in, for cerebral malaria, nitric oxide formation and, 226
Immunosuppression
vs. HIV genital shedding, 57

in paracoccidioidomycosis, 1263
Immunosuppressive therapy
aspergillosis, mouse model, 222
in *Pneumocystis carinii* suppression, rat model, 901
Indinavir, for HIV infection, glycoprotein binding in, 1063
Infants (*See* Pediatric patients)
Infectious mononucleosis, antibody-dependent cellular cytotoxicity in, 38
Influenza
swine, transmission from pigs, 7
vaccination
of health care workers, reduced mortality in elderly patients, 1
heat-labile enterotoxin adjuvant for, 352
purified recombinant hemagglutinin in, 342
Intercellular adhesion molecule-1
cerebrospinal fluid, in subacute sclerosing panencephalitis, 689
expression, in *Rickettsia conorii* infection, 1142
Interferon(s), for hepatitis C, response vs. quasispecies heterogeneity, 1101
Interferon-α, for hepatitis C, 316, 1294
Interferon-β, production, in coxsackievirus group B vascular endothelial cell infection, 693
Interferon-γ
macrophages treated with, nitrite generation and, 130
production
in *Bordetella pertussis* infection, 1246
in *Brugia malayi* infection, factors affecting, 1276
in hepatitis C, 681
in HIV infection, vs. disease progression, 47
in influenza vaccination, 342
Leishmania major–specific T cells, 151
in leishmaniasis, 737
in pentoxifylline therapy, for HIV infection, 1210
in rhinovirus-specific T cells, 1108
in tuberculosis skin tests, cattle model, 1251
in *Trypanosoma brucei brucei* proliferation, tyrosine kinases in, mouse model, 669
Interleukin(s), production
in HIV infection, vs. disease progression, 47
in influenza vaccination, 342
intrahepatic, in hepatitis C, 681
Interleukin-1, production, autologous platelet interaction in, 123
Interleukin-1 receptor antagonist, production, in fever of unknown origin, 191
Interleukin-1 soluble receptor, production, in sepsis, 118
Interleukin-1β
brain cell response to, 478
cerebrospinal fluid, in subacute sclerosing panencephalitis, 689
production
in fever of unknown origin, 191
in HIV infection, 1507
in *Rickettsia conorii* infection, 1142
Interleukin-2
production
in boutonneuse fever, 142
Entamoeba histolytica liver abscess, gerbil model, 1176
in pentoxifylline therapy, for HIV infection, 1210
subcutaneous, in HIV infection, 781
Interleukin-2 fusion protein (DAB_{389}IL-2), HIV inhibition by, in peripheral blood mononuclear cell culture, 790
Interleukin-2 soluble receptor, production, in boutonneuse fever, 142
Interleukin-4
macrophages treated with, nitrite generation and, 130
production
in *Brugia malayi* infection, factors affecting, 1276
in *Entamoeba histolytica* liver abscess, gerbil model, 1176
in rhinovirus-specific T cells, 1108
Interleukin-5, production
in *Brugia malayi* infection, factors affecting, 1276
in rhinovirus-specific T cells, 1108
Interleukin-6
antibodies to, herpes simplex virus reactivation inhibition by, 821
production
in antibiotic therapy, 1255
in cystic fibrosis, 638
in fever of unknown origin, 191
Interleukin-8
in middle ear effusions, 474
in *Mycobacterium avium* infection, in vitro model, 891
production
in cystic fibrosis, 638
in monocytes, rhinovirus-induced, 323
respiratory syncytial virus induction, in airway epithelial cells, 497
Interleukin-10
in nitric oxide synthase production, in macrophage culture, 1008
production
in diffuse leishmaniasis, 737
in sepsis, 118
in tumor necrosis factor production, in macrophage culture, 1008
Interleukin-12
in leishmaniasis resistance, mouse model, 1477
in pulmonary histoplasmosis, mouse model, 905
in SCID mouse, for *Neisseria meningitidis* serogroup C immune response study, 84
Interleukin-13, production, in sepsis, 118
Intestine
Clostridium botulinum colonization, in Crohn's disease, 633
immunoglobulin induction in, in HIV intranasal immunization, mouse model, 292
Intraepithelial neoplasia, cervical
condylomata acuminata and, 743
human papillomavirus in, cytotoxic T cell response to viral proteins, 927
Intravenous immunoglobulins (*See* Immunoglobulin(s), intravenous)
Iron chelation therapy, for cerebral malaria, nitric oxide formation and, 226
Iron overload, in *Candida albicans* infection, T helper cell response in, mouse model, 1467
ISIS phosphorothioate oligonucleotides, antiviral, retinal effects, rabbit and pig models, 1308
Islet cell antibodies, induction by enteroviruses, 554
Isoenzymes, *Pneumocystis carinii*, diversity, rodent models, 655
Ivermectin, diethylcarbamazine with, for *Wuchereria bancrofti* infection, 489
IVIG (*See* Immunoglobulin[s], intravenous)
Ixodes ticks, attachment duration, vs. Lyme disease risk, 996

Jennerian vaccine, rotaviruses, mouse model, 330

Kaposi's sarcoma
Epstein-Barr virus in, Uganda, 947
Kaposi's sarcoma–associated herpes virus associated with (*See* Human herpesvirus type 8)
Keratitis, herpes simplex virus, inhibition by interleukin-6 antibodies, 821

Laboratories, for poliomyelitis surveillance
global network, S113

Pan American region, S43
western Pacific, S117
Lactobacillus reuteri, in *Cryptosporidium parvum* infection, mouse model, 218
Lamivudine, for HIV infection
didanosine and zidovudine with, 1051
susceptibility to, 561
Leishmania aethiopica, cytokine production by, 737
Leishmania major, T cell priming, factors affecting, 151
Leishmaniasis
cytokine production in, diffuse vs. localized forms, 737
visceral, acquired resistance in, mouse model, 1477
Leucine aminopeptidase, *Pneumocystis carinii*, diversity, rodent models, 655
Leukemia, adult T cell, human T cell lymphotropic/leukemia virus type 1 antibodies in, 716
Leukocyte culture, in cytomegalovirus infection prediction, in HIV infection, 302
Leukocyte esterase test, in urethritis screening, 833
Leukoplakia, opportunistic viruses in, in HIV infection, 1324
Lipids, *Pneumocystis carinii*, transfer from alveolar epithelial cells, 661
Lipooligosaccharide enzyme immunoassay, for *Haemophilus ducreyi* antibodies, 1390
Lipopolysaccharide (endotoxin)
antiinflammatory cytokines induced by, 118
in bactericidal/permeability-increasing protein release, 108
brain cell response to, 478
Campylobacter jejuni, cross-reactive with gangliosides, in Guillain-Barré syndrome, 729
Escherichia coli O157:H7, mouse model, 611
neutralization, mouse model, 621
platelet effects, mouse model, 1404
production
in antibiotic therapy, 1255
in septic shock, circadian aspects, 1283
Shigella, immunoglobulin G subclass response to, 1128
Lipoteichoic acid, in bactericidal/permeability-increasing protein release, 108
Liver
abscess, *Entamoeba histolytica*, cytokine responses in, gerbil model, 1176
cytokine production in, in hepatitis C, 681
transplantation, candidates for, hepatitis C virus genotypes in, 448
Loa loa infection, immunoglobulin G subclasses in, 158
Long-term care, health care worker influenza vaccination in, elderly patient mortality reduction from, 1
Lung
cancer, condylomata acuminata and, 743
cytomegalovirus replication in, in immunodeficiency, mouse model, 309
immunoglobulin induction in, in HIV intranasal immunization, mouse model, 292
Lyme disease (*See also Borrelia burgdorferi*)
antibody tests for, false-positive, in nonendemic region, 466
arthritogenesis in, mouse model, 1000
epidemiology, 720, 1432
risk, vs. tick attachment duration, 996
vaccination, mouse model, 91
Lymph nodes, aspiration, in HIV treatment monitoring, 1202
Lymphocytes (*See* B cells; T cell[s])
Lymphoma
central nervous system, human herpesvirus type 8 in, 1193
opportunistic viruses in, in HIV infection, 1324
Lymphotoxin production, in pentoxifylline therapy, for HIV infection, 1210
Macrophage(s)
alveolar, in *Candida albicans* phagocytosis, surfactant protein A in, 421
apoptosis, from *Shigella*, 470
Candida killing activity, 214
Histoplasma capsulatum infection, yeast cell wall alterations in, 1538
in *Leishmania major*–specific T cell priming, 151
nitric oxide production in, age-related decline in, mouse model, 1004
nitrite generation in, interleukin-4 effects on, 130
Macrophage inflammatory proteins, production, in chemokine stimulation, 478
Macrophage-inhibitory proteins, in *Mycobacterium avium* infection, in vitro model, 891
Malaria
cerebral
iron chelation therapy for, nitric oxide formation and, 226
mouse model, 1480
falciparum, clinical manifestations, with mosquito challenge, 915
treatment, in Brazil, 1544
vaccination, in Tanzania, 921
Malate dehydrogenase, *Pneumocystis carinii*, diversity, rodent models, 655
Malic enzyme, *Pneumocystis carinii*, diversity, rodent models, 655
Mannose-binding protein, *Mycobacterium avium* complex interaction with, 1159
Markers, surrogate
for HIV infection therapies, 576
perspective, 237
Maternal transmission, HIV infection (*See* Human immunodeficiency virus infection type 1, transmission, vertical)
Measles
diagnosis, immunoglobulin M capture enzyme immunoassay in, 195
vaccination
in passively acquired antibody presence, macaque model, 524
in poliomyelitis eradication program, S268, S272
Mefloquine, with vaccines, 871
Meningitis
Borrelia, newly identified, mouse model, 1243
Streptococcus pneumoniae, serotype differences in, rabbit model, 979
Meningococcal polysaccharide, serogroup C, immune response to, in interleukin-12–treated SCID mouse, 84
Meningococcal vaccines
group B, animal models, 364
polysaccharide-protein conjugate, 200
Meropenem, in chemical mediator release, 1255
Methicillin, resistance to, *Staphylococcus epidermidis*, 462
Mexico virus, epidemiology, United Kingdom, 951
Microfilariasis
brugian, cytokine measurement in, factors affecting, 1276
Loa loa, immunoglobulin G subclasses and, 158
Wuchereria bancrofti, circulating antigen of, treatment effects on, 489
Microglia, chemokine response, 478
β_2-Microglobulin, in cerebrospinal fluid, in HIV infection, 434
Microimmunofluorescence assay, indirect, for chlamydial hsp60 antibodies, 1153
Microsporidiosis, epidemiology, in immunocompetence, Netherlands, 1020
Migratory response, to chemokines, in brain cells, 478
Miller Fisher syndrome, cross-reactive antibodies in, gangliosides and *Campylobacter jejuni*, 729
Monoclonal antibody(ies)
Candida, in neutropenia, mouse model, 1169
HIV, selection for treatment trials, 1056
interleukin-12, in pulmonary histoplasmosis, mouse model, 905

Monoclonal antibody–capture enzyme immunoassay
for measles diagnosis, 195
for polio vaccine response, S264
Monocyte(s)
Mycobacterium tuberculosis infection, HIV replication enhancement, 1531
rhinovirus-induced interleukin-8 production in, 323
Monocyte chemoattractant/chemotactic protein-1
production, in chemokine stimulation, 478
respiratory syncytial virus induction, in airway epithelial cells, 497
Mononuclear cells, cytokine production in, autologous platelet interaction in, 123
Moraxella catarrhalis, colonization, otitis media and, 1440
Mortality, elderly patients in long-term care, health care workers, influenza vaccination effects on, 1
Mosquitoes, challenge with, in *Plasmodium falciparum* human experimentation, 915
mrp gene product, in group A streptococci, plasmin-like activity, 1115
Mucosal immune response
HIV infection, in women, 265
HIV intranasal immunization, mouse model, 292
poliomyelitis vaccine, oral with inactivated virus, S215, S228
Multiple sclerosis, cerebrospinal fluid cytokines in, 689
Multiplex polymerase chain reaction, in sexually transmitted disease diagnosis, 583
Mumps virus, Urabe vaccine strain, molecular characterization, 1548
Murine rotavirus infection, immune responses in, mouse model, 1317
Mutation
cytomegalovirus, resistance development in, 1087
Enterococcus faecalis BM4281, vancomycin resistance in, 598
hepatitis B virus, 1285
core protein, disease progression and, 1093
in vaccine, chimpanzee model, 511
Vibrio cholerae O1 El Tor, 1134
Mycobacterium avium
infection
in HIV infection, cytokine effects on, in vitro model, 891
in simian immunodeficiency virus infection, from potable water, 184
mannose-binding protein interaction with, 1159
Mycobacterium bovis infection, diagnosis, ESAT-6 antigen detection in, cattle model, 1251
Mycobacterium tuberculosis (*See also* Tuberculosis)
antigen, T cell receptor activation, in HIV infection, 429
Mycophenolate mofetil, in *Pneumocystis carinii* suppression, rat model, 901
Myeloperoxidase, granulocyte colony-stimulating factor effects, 1184
Myocarditis, coxsackievirus group B infection in, 693

Nalidixic acid, for *Shigella* diarrhea, 1527
Nasal lavage, in cystic fibrosis, cytokine detection in, 638
Nasopharyngeal carcinoma, in Epstein-Barr virus infection, antibody-dependent cellular cytotoxicity in, 38
National immunization days, for polio (*See* Poliomyelitis vaccination)
Neisseria meningitidis
serogroup C, immune response to, in interleukin-12–treated SCID mouse, 84
vaccines, animal models, 364
Neonatal infections
cytomegalovirus, treatment with ganciclovir, 1080
from *Escherichia coli* colonization, 606
HIV (*See also* Human immunodeficiency virus infection type 1, transmission, vertical)
anti-HIV immunoglobulin for, 283
diagnosis, 1333
early detection, RNA amplification in, 707
rabbit model, 1337
tetanus, vaccination for, in poliomyelitis eradication program
Egypt, S277
Philippines, S272
Trypanosoma cruzi, long-lasting antibodies in, 1272
Neopterin, in cerebrospinal fluid, in HIV infection, 434
Nested touchdown polymerase chain reaction, in chlamydial infection diagnosis, 1523
Neurocysticercosis, treatment, serologic evolution after, 486
Neurologic disease
cerebrospinal fluid cytokines in, 689
in HIV infection, dexamethasone effects on, mouse model, 1368
malaria, mouse model, 1480
Neutralization assay
for HIV antibodies, 764
in selection for clinical trials, 1056
for polio vaccine response, S264
Neutropenia
anti-candidal monoclonal antibody in, mouse model, 1169
from ganciclovir, in cytomegalovirus infection, 1080
Neutrophils
augmentation by granulocyte colony-stimulating factor, in fungal infection, 1012
cytokine effects on, in *Mycobacterium avium* infection, in vitro model, 891
oxidative function, granulocyte colony-stimulating factor effects, 1184
response to group B streptococci, C5 and C5a-ase (complement system)
in, mouse model, 847
Nevirapine, for HIV infection
high-dose, 966
resistance to, 1502
susceptibility, 561
Nitric oxide, generation
age-related decline in, mouse model, 1004
in iron chelation therapy, in cerebral malaria, 226
Nitric oxide synthase, production, factors affecting, in macrophage culture, 1008
Nitrites, generation in interleukin-4–treated macrophage culture, 130
Nonstructural protein 3, hepatitis C virus, T cell response to, interferon-α effects on, 1294
Normalized area under the curve, in HIV infection therapy clinical trials, 576
Nose
colonization, otitis media and, 1440
HIV-specific IgA in, in women, 265
immunization in, for HIV, mouse model, 292
Nosocomial infection, *Serratia marcescens*, epidemiology, California, 992

Oligonucleotides, phosphorothioate, antiviral, retinal effects, rabbit and pig models, 1308
Opsonin receptors, granulocyte colony-stimulating factor effects, 1184
Opsonization, *Mycobacterium avium* complex, mannose-binding proteins in, 1159
Oral tissues
human herpesvirus type 8 variants in, in HIV infection, 703
opportunistic viruses in, in HIV infection, 1324
OspA-based DNA vaccine, *Borrelia burgdorferi*, mouse model, 91
Otitis media
effusion in, interleukin-8 in, 474
nasopharyngeal colonization and, 1440
Outbreaks
Haemophilus ducreyi infection, antibody assays in, 1390

hepatitis C, in hemodialysis unit, 26
Mexico virus, United Kingdom, 951
poliomyelitis, after vaccination, Jordan, S62
Salmonella infection, from alfalfa sprouts, 876
Serratia marcescens wound infection, California, 992
toxoplasmosis, foodborne, Korea, 1280
Outer surface protein A, *Borrelia burgdorferi*, in vaccine, 400
Oxidation, neutrophil, granulocyte colony-stimulating factor effects, 1184

p24 antigen
clearance, anti-HIV immunoglobulin for, 283
detection, perinatal, 1333
P fimbriae, adhesin genes, *Escherichia coli*, epidemiology, 983
Pan American Regional Poliomyelitis Laboratory Network, in poliomyelitis surveillance, S43
PapG adhesins, uropathic *Escherichia coli*, receptor specificities, 373
papG genes, *Escherichia coli*, epidemiology, 983
Paracoccidioidomycosis, immunosuppression in, 1263
Parainfluenza virus infection, in pediatric patients, epidemiology and clinical impact, 807
Paralysis surveillance, in poliomyelitis eradication (*See* Poliomyelitis eradication, acute flaccid paralysis surveillance in)
Pediatric patients (*See also* Neonatal infections)
bloody diarrhea in, etiology and treatment, in Bolivia, 1527
Bordetella pertussis infection in, helper T cell activation in, 1246
cerebral malaria in, iron chelation therapy for, nitric oxide formation and, 226
enterovirus infection in, islet cell antibody induction in, 554
Escherichia coli infection in, enteropathogenic, characterization, 1382
Guillain-Barré syndrome epidemiology, Latin America, S160
HIV infection in (*See also* Human immunodeficiency virus infection type 1, transmission, vertical)
anti-HIV immunoglobulin for, 283
vs. cytokine pattern, 47
diagnosis, 1333
mortality risk vs. disease markers, 1029
prevention with maternal zidovudine therapy, 971
rabbit model, 1337
treatment, 1039
middle ear effusions in, interleukin-8 in, 474
otitis media in, nasopharyngeal colonization and, 1440
parainfluenza virus infection in, epidemiology, 807
respiratory syncytial virus infection in
CD23 B cell increase in, 32
severity vs. virus strain, 814
Pelvic inflammatory disease, chlamydial
antibody measurement in, 1153, 1453
treatment, macaque model, 648
Penicillin(s)
resistance to
Neisseria gonorrhoeae, 1396
Streptococcus pneumoniae, 1413
for *Streptococcus gordonii* endocarditis, tolerance in, 70
Pentoxifylline
for HIV infection, viral load reduction in, 1210
in nitric oxide synthase production, in macrophage culture, 1008
in tumor necrosis factor production, in macrophage culture, 1008
Peripheral blood progenitor cell transplantation, cytomegalovirus infection monitoring in, 1490
Perspective, surrogate marker evaluation, in HIV infection, 237
Pertussis
helper T cell activation in, 1246
vaccination, immunodominant domains in, 1423
Phagocytosis
in brain, trafficking of, 478
Candida albicans, surfactant protein A in, 421
granulocyte colony-stimulating factor effects, 1184
Pharyngitis, *Arcanobacterium haemolyticum*, antibody response in, 1515
6-Phosphogluconate dehydrogenase, *Pneumocystis carinii*, diversity, rodent models, 655
Phospholipase activity, as *Cryptococcus neoformans* virulence factor, mouse model, 414
Phosphoproteins, cytomegalovirus antibodies specific to, 533
Phosphorothioate oligonucleotides, antiviral, retinal effects, rabbit and pig models, 1308
Phosphorylation, *Trypanosoma brucei brucei* proliferation, interferon-γ–stimulated, mouse model, 669
Pigs, swine influenza virus transmission from, 7
Plasmid DNA analysis, in *Shigella sonnei* characterization, 864
Plasmin-like activity, in group A streptococci, 1115
Plasminogen, in group A streptococci plasmin-like activity acquisition, 1115
Plasmodium falciparum infection
clinical manifestations, with mosquito challenge, 915
treatment, in Brazil, 1544
vaccination, in Tanzania, 921
Platelets
lipopolysaccharide effects on, mouse model, 1404
mononuclear cell interaction with, cytokine production and, 123
Pneumococci *(See Streptococcus pneumoniae)*
Pneumocystis carinii
dihydropteroate synthase polymorphisms in, 482
isoenzyme diversity, rodent models, 655
lipid transfer from alveolar epithelial cells, 661
Pneumocytes, *Aspergillus fumigatus* conidia binding and germination on, 146
Pneumonitis
cytomegalovirus, in immunodeficiency, mouse model, 309
Pneumocystis carinii, immunosuppressant effects on, rat model, 901
Poliomyelitis
epidemiology, S4
Africa, S16, S20, S24
Americas, S37
Angola, S24
China, S105, S122
former Soviet Union, S76
Gambia, S254
global, S165
Indochina, 1233
Jordan, S62
Mediterranean region, S50
Namibia, S30
Saudi Arabia, S71
southeast Asia, S89
Uzekistan, S82
western Pacific, S97
eradication (*See* Poliomyelitis eradication)
in nonhuman primates, S286
pathophysiology, S286
vaccination for (*See* Poliomyelitis vaccination)
viruses of (*See* Polioviruses)
Poliomyelitis eradication
acute flaccid paralysis surveillance in, S4, S146
Africa, S10, S20
Americas, S37
Cambodia, S173

China, S105, S122
Egypt, S277
former Soviet Union, S76
Guillain-Barré syndrome mortality and morbidity assessment implications for, S151
last American case, S281
Latin America, S160
Mediterranean region, S50
method sensitivity, S135
Namibia, S30
southeast Asia, S89
United Kingdom, S156
virus excretion duration and, S176
Americas
acute flaccid paralysis surveillance in, S37
laboratory issues, S43
benefits, S4
biologic principles, S286
certification for
Americas, S281
laboratory in, S113
United Kingdom, S156
epidemiologic aspects (*see* Poliomyelitis, epidemiology)
laboratory issues, Americas, S43
obstacles to, S4
overview, S1
primary health care impact
Egypt, S277
Philippines, S272
problems with
in Africa, S10, S16, S20
Cambodia, S173
Egypt, S56
former Soviet Union, S76
Gypsy population, S86
laboratory equipment shortage, S117
Uzekistan, S82
western Pacific, S97
progress toward, S4
status
Africa, S10, S16, S20, S24
Americas, S281
Angola, S24
China, S105
Egypt, S56
former Soviet Union, S76
Gypsy population, S86
Jordan, S62
Mediterranean region, S50
Namibia, S30
Philippines, S272
Saudi Arabia, S71
southeast Asia, S89
Uzekistan, S82
western Pacific, S97
strategies for, S4
Africa, S10, S16, S20
Americas, S37, S281
China, S210
Egypt, S56
former Soviet Union, S76
Gypsy population, S86
Jordan, S198
Namibia, S30
national immunization days (*See* Poliomyelitis vaccination)
Pakistan, S205
Philippines, S272
southeast Asia, S89
western Pacific, S97, S268
surveillance in (*See also* Poliomyelitis eradication, acute flaccid paralysis surveillance in)
China, S122
infrastructure for, S146
laboratories for
global network, S113
Pan American region, S43
western Pacific, S117
recommendations for, S146
sensitivity evaluation in, S135, S141
United Kingdom, S156
weaknesses in, S156
vaccines in (*see* Poliomyelitis vaccination)
Poliomyelitis vaccination
additional interventions during, S183, S194
Egypt, S277
Philippines, S272
western Pacific region, S268
Africa, S4, S10, S20
with antimalarial drugs and other vaccines, 871
China, S105
delivery strategies for, S183
diarrhea effects on, Brazil, S258
efficacy, S286
monoclonal antibody–based test for, S264
seasonal effects on, S254
Egypt, S56
failure, diarrhea in, S258
former Soviet Union, S76
immunogenicity in Mayan population, 545
improvements in, S4
inactivated, S4
followed by oral vaccine, Oman, S235
mouse model, 441
Mediterranean region, S50
mopping-up campaigns for, S4
China, S105
Egypt, S56
Namibia, S30
national immunization days, S4
China, S105
Egypt, S56
former Soviet Union, S76
Latin America, S189
Mediterranean region, S50
Pakistan, S205
Philippines, S272
southeast Asia, S89
state of the art, S183
western Pacific, S97, S194
oral
deuterium-stabilized, S4, S247
with inactivated virus, S215, S228
Romania, S241
outbreak after, in Jordan, S62
potency testing, S113
routine, S4
vs. mass programs for, immunogenicity in, S198
season for, Gambia, S254

selection, S4
sequential dose schedule, S228
subnational immunization days, S183, S194
supplemental campaign, target age for, China, S210
thermostable vaccine for, S247
type 3 virus in, mouse model, 441
Polioviruses
antibodies to
assay for, S113
in routine vs. mass vaccination programs, Jordan, S198
culture, S43
in global laboratory network, S113
excretion, acute flaccid paralysis surveillance and, S176
genetic characterization, S113
inactivation, S286
reservoir for, S286
survival in environment, S286
transmission, S286
wild
active search for, S43
Africa, S20
Americas, S37, S43
Angola, S24
China, S105, S122
elimination, in Americas, S281
excretion, acute flaccid paralysis surveillance and, S176
Gypsy population, S86
Indochina, 1233
Jordan, S62
Namibia, S30
Saudi Arabia, S71
southeast Asia, S89
surveillance for
sensitivity evaluation in, S135, S141
United Kingdom, S156
western Pacific, S97
Polymerase chain reaction
with BOX primers, for persistent *Streptococcus pneumoniae* carrier detection, 590
for cytomegalovirus infection
monitoring, in bone marrow transplantation, 1490
prediction, in HIV infection, 302
susceptibility testing, 1087
for hepatitis B virus mutant detection, 511
for hepatitis C virus genotyping, 685
for hepatitis C virus hypervariable region amplification, 505
for HIV infection diagnosis
perinatal, 707, 1333
in pregnancy, 57
viral load measurement in, 438
for human herpesvirus type 8 detection, 1193
multiplex, for sexually transmitted disease diagnosis, 583
nested, for human herpesvirus type 8 variant amplification, 703
nested touchdown, for chlamydial infection diagnosis, 1523
reverse transcription, for hepatitis G virus detection, 450, 454
reverse-transcription competitive, for hepatitis C RNA semiquantitative analysis, 681
for swine influenza virus antigen comparison, 7
for T cell characterization, in HIV exposure, 272
Pork ingestion, toxoplasmosis from, in Korea, 1280
Porphyromonas gingivalis, lipopolysaccharide from, platelet response to, mouse model, 1404
Pregnancy
cytomegalovirus infection diagnosis in, 944
HIV infection in (*See also* Human immunodeficiency virus infection type 1, transmission, vertical)
anti-HIV immunoglobulin for, 283
gp41 envelope glycoprotein carboxy region antibody response in, 63
viral shedding in, factors affecting, 57
virus load in, 172
tuberculosis risk in, 1025
Venezuelan equine encephalitis in, 828
Preterm delivery, maternal vaginal *Escherichia coli* colonization and, 606
Prevotella bivia, Gardnerella vaginalis symbiotic relationship with, in bacterial vaginosis, 406
Prevotella intermedia, lipopolysaccharide from, platelet response to, mouse model, 1404
Progenitor cells
inhibition, dengue virus in, in vitro model, 1497
transplantation, cytomegalovirus infection monitoring in, 1490
Proguanil
for malaria, 1544
with vaccines, 871
Proliferation assay, for CD4 T cells, in tetanus toxin response, 382
Prophylaxis (*See also* Vaccination)
antibiotic, in Lyme disease, tick attachment duration and, 996
N-Propionylated polysialic acid–recombinant meningococcal porin conjugate, for meningococci vaccination, animal models, 364
Protease inhibitors (*see also specific drugs*)
for HIV infection, glycoprotein binding, 1063
Protein binding, of protease inhibitors, 1063
Proteosomes, in HIV intranasal immunization, mouse model, 292
Provirus, HIV, measurement, 247
prsG genes, *Escherichia coli*, epidemiology, 983
Pulsed-field gel electrophoresis, in *Shigella sonnei* characterization, 864
Pyrogenic cytokines, in fever of unknown origin, 191

Quality assurance, in polio surveillance laboratories, S113
Quinine, for malaria, 1544

Random amplified polymorphic DNA analysis, group A streptococci T1M1 serotype identification, 392

RANTES (chemokine), respiratory syncytial virus induction, in airway epithelial cells, 497
Rapamycin, immunosuppression, aspergillosis, mouse model, 222
Reactive arthritis, in enterobacterial infection, T cell subsets in, 1121
Receptor affinity purification, *Haemophilus influenzae* adhesin, 77
Relapsing fever, newly identified *Borrelia* in, mouse model, 1243
Reporter gene induction assay, for human T cell lymphotropic/leukemia virus type I antibodies, 716
Resistance
cidofovir, 1087
ciprofloxacin, 1396
cytomegalovirus, 1087
enterococci, 232
Enterococcus faecalis BM4281, 1087
fluoroquinolones, 1396
ganciclovir, 1087
glycopeptides, 598
HIV, 1502
ribavirin, 176
test methods for, 561
Loa loa, 158
methicillin, 462
multiple, enterococci, 232

Neisseria gonorrhoeae, 1396
nevirapine, 1502
penicillin
Streptococcus gordonii, 70
Streptococcus pneumoniae, 1413
Pneumocystis carinii, 482
ribavirin, 176
Streptococcus pneumoniae, 590, 1413
sulfa drugs, 482
vancomycin, 598
zidovudine, 1502
Respiratory infection
Bordetella pertussis, helper T cell activation in, 1246
Chlamydia pneumoniae, rapid diagnosis, 1523
Histoplasma capsulatum, interleukin-12 in, mouse model, 905
parainfluenza virus, in pediatric patients, 807
Streptococcus pneumoniae, prevention with intranasal immunization, mouse model, 839
Respiratory syncytial virus
bronchiolitis, CD23 B cell increase in, 32
infection
group B, immunoprophylaxis, cotton rat model, 932
severity, vs. virus strain, 814
in RANTES production stimulation, in airway epithelial cells, 497
vaccination, maternal, infant protection in, guinea pig model, 935
Restriction endonuclease analysis, group A streptococci T1M1 serotype identification, 392
Restriction fragment length polymorphism analysis
hepatitis B virus genotypes, 1285
Mycobacterium tuberculosis epidemiology, Arkansas, 1440
Vibrio cholerae O1 El Tor strains, 1134
Retina, viral toxicity to, rabbit and pig models, 1308
Reverse transcriptase, mutations, HIV drug susceptibility and, 561
Rhinoviruses
in interleukin-8 induction, in monocytes, 323
T cells recognizing, epitope recognition studies, 1108
Rhizopus arrhizus infection, treatment with granulocyte colony-stimulating factor, 1012
Ribavirin
for hepatitis C, 1294
for HIV infection, virus drug sensitivity after, 176
Ribotyping
streptococci, group A, T1M1 serotype identification, 392
Vibrio cholerae O1 El Tor strains, 1134
Rickettsia conorii
boutonneuse fever, cytokine secretion in, 142
infection, adhesive molecule expression in, 1142
Rightward open-reading frame-1 protein, Epstein-Barr virus, antibody response to, 38
Ritonavir, for HIV infection, glycoprotein binding in, 1063
RNA
hepatitis C virus, measurement, 681
hepatitis G virus, detection, 1302
human immunodeficiency virus (*See* Human immunodeficiency virus, RNA)
Rotaviruses
infection, immune responses in, mouse model, 1317
vaccination, heterotypic protection after, mouse model, 330
Rubella, vaccination, immune response to, 749

Sabin polio vaccine, immunogenicity in Mayan population, 545
Saliva
HIV-specific IgA in, in women, 265
opportunistic viruses in, in HIV infection, 1324
Salmonella
epidemiology, Bangladesh, 734
serotype *stanley*, in alfalfa sprouts, 876
in T cells, in reactive arthritis, 1121
Salmonella typhi
lipopolysaccharide from, platelet response to, mouse model, 1404
vaccination for, with antimalarial drugs and other vaccines, 871
Salmonella typhimurium, antigen, T cell receptor activation, in HIV infection, 429
Salpingitis, *Chlamydia trachomatis*, treatment, macaque model, 648
Sample size, for plasma RNA measurement, in HIV infection therapy clinical trials, 576
Saquinavir, for HIV infection
glycoprotein binding in, 1063
response monitoring in, 1202
Sarcoma, Kaposi's (*See* Human herpesvirus type 8; Kaposi's sarcoma)
SC-52151 protease inhibitor, for HIV infection, glycoprotein binding in, 1063
Schistosoma mansoni, treatment, immunoglobulin response after, 493
Selectins, expression, in *Rickettsia conorii* infection, 1142
Sepsis
antiinflammatory cytokine responses in, 118
gram-negative, endotoxin neutralization in, mouse model, 621
platelet-monocyte interactions in, cytokine production and, 123
Septic shock, circadian time structure, 1283
Seroconversion
in hepatitis B infection, core protein mutations after, 1093
in HIV infection (*See* Human immunodeficiency virus infection, seroconversion in)
Serotonin, formation, in platelet response to lipopolysaccharide, mouse model, 1404
Serratia marcescens, wound infection, epidemiology, California, 992
Sewage treatment, poliovirus survival in, S286
Sexually transmitted diseases
chancroid, antibodies in, enzyme immunoassays for, 1390
epidemiology, San Francisco, 1519
Escherichia coli urinary tract infection, 989
hepatitis A, in homosexual and bisexual populations, 1225
hepatitis G (GB virus C infection), 1025
transmission, core groups in, 1519
ulcers in, diagnosis, clinical vs. laboratory, HIV infection and, 583
urethritis, screening and management, East African men, 833
Shiga-like toxin, in *Escherichia coli* O157:H7 infection, mouse model, 611
Shigella
diarrhea, treatment, 1527
epidemiology, Bangladesh, 734
immunoglobulin G subclass response to, 1128
in macrophage apoptosis induction, 470
Shigella sonnei, characterization, 864
Shock, septic, circadian time structure, 1283
trans-Sialidase inhibition assay, for *Trypanosoma cruzi* antibodies, 1272
Sicca syndrome, human T cell lymphotropic/leukemia virus type I antibodies in, 716
Simian immunodeficiency virus infection
Enterocytozoon bieneusi infection in, rhesus monkey model, 1016
Mycobacterium avium infection in, from potable water, 184
Simian rotavirus infection, immune responses in, mouse model, 1317
Sirolimus
immunosuppression, aspergillosis, mouse model, 222
in *Pneumocystis carinii* suppression, rat model, 901
Skin tests, bovine tuberculosis, 1251
Small round-structured viruses, epidemiology, United Kingdom, 951
Smallpox, vaccinia vaccination for, immune response to, vs. administration route, 756

Staphylococcus epidermidis, methicillin-resistant, endophthalmitis, intravitreal treatment, rabbit model, 462
Streptococcal infection
  group A
    T1M1 serotype, epidemiology, Finland, 392
    toxic shock–like syndrome, transmission, 723
  group B
    C5 and C5a-ase in, mouse, 847
    vaccination, mouse model, 1237
Streptococci, group A, plasmin-like enzymatic activity in, 1115
Streptococcus gordonii, endocarditis, penicillin for, tolerance in, 70
Streptococcus pneumoniae
  colonization
    in HIV infection, 590
    otitis media and, 1440
  meningitis, serotype differences in, rabbit model, 979
  resistance in
    in HIV infection, 590
    penicillin, 1413
  vaccination
    in HIV infection, 975
    mouse model, 839
Streptococcus pyogenes
  group A, T1M1 serotype, epidemiology, Finland, 392
  toxic shock–like syndrome, transmission, 723
Streptokinase, in group A streptococci plasmin-like activity acquisition, 1115
Subacute sclerosing panencephalitis, cerebrospinal fluid cytokines in, 689
Sulfa drugs, resistance to, *Pneumocystis carinii*, 482
Surfactant protein A, in *Candida albicans* phagocytosis, 421
Surrogate markers for HIV infection therapies, 237, 576
Surveillance, in poliomyelitis eradication (*See* Poliomyelitis eradication, surveillance in)
Susceptibility testing
  cytomegalovirus, 1087
  human immunodeficiency virus, 561
Swine influenza, transmission from pigs, 7
Syphilis, diagnosis, clinical vs. laboratory, 583

T cell(s)
  apoptosis in, herpes simplex virus–induced, 1220
  CD4
    epitope repertoire, in tetanus toxin response, 382
    in hepatitis C, interferon-α effects on, 1294
    in HIV infection
      vs. exposure without seroconversion, 272
      interleukin-2 effects on, 781
      maternal-infant transmission risk and, 567
      vs. mortality risk, 1029
      vs. rate of decline in, 775
      as surrogate marker, 237
  CD8
    antigen-presenting cells for, in reactive arthritis, 1121
    maternal-infant transmission risk and, 567
    vs. quantitative HIV measures, 247
  cytolytic, polyclonal response, in HIV infection, 1360
  enterobacteria-infected, in reactive arthritis, 1121
  helper
    activation in *Bordetella pertussis* infection, 1246
    hepatitis B virus core protein mutations in, 1093
    response to iron overload, in *Candida albicans* infection, mouse model, 1467
  HIV transmission to, *Mycobacterium tuberculosis* effects on, 1531
  HIV-infected, in disease transmission, rabbit model, 1337
  hyporesponsiveness, in paracoccidioidomycosis, 1263
  Leishmania major–specific, priming, 151
  rhinovirus-specific, epitope recognition studies, 1108
  surface markers of, in chronic fatigue syndrome, 136
  Th-2 response, in respiratory syncytial virus bronchiolitis, 32
T cell receptors
  bacterial antigen activation, in HIV infection, 429
  junctional sequences, in HIV infection, vs. exposure without seroconversion, 272
Tacrolimus (FK506)
  immunosuppression, aspergillosis, mouse model, 222
  in *Pneumocystis carinii* suppression, rat model, 901
Taenia solium infection, treatment, serologic evolution after, 486
Teicoplanin, for *Enterococcus faecalis* BM4281 endocarditis, rabbit model, 598
Terminal deoxytransferase–mediated dUTP nick end-labeling method, T cell apoptosis, herpes simplex virus–induced, 1220
Tetanus, neonatal, vaccination, in poliomyelitis eradication program
  Egypt, S277
  Philippines, S272
Tetanus toxin, CD4 T cell epitope response to, 382
Tetracycline
  for boutonneuse fever, 142
  for malaria, 1544
  resistance to, *Neisseria gonorrhoeae*, 1396
Tetrazolium dye method, for HIV susceptibility testing, 561
Th-2 response, in respiratory syncytial virus bronchiolitis, 32
Thrombocytopenia, from ganciclovir, in cytomegalovirus infection, 1080
Ticks, in disease transmission
  attachment duration, vs. Lyme disease risk, 996
  epidemiology, California, 1432
Tolerance, penicillin, *Streptococcus gordonii* endocarditis, 70
Toxic shock, antibiotic-induced chemical mediator release in, 1255
Toxic shock–like syndrome, *Streptococcus pyogenes*, transmission, 723
Toxins
  Escherichia coli O157:H7, mouse model, 611
  tetanus, CD4 T cell epitope response to, 382
Toxoplasmosis, foodborne, epidemiology, Korea, 1280
Transfusion, babesiosis transmission in, 1259
Transplantation
  bone marrow
    aspergillosis epidemiology in, 1459
    cytomegalovirus infection monitoring in, 1490
  immunodeficiency in, cytomegalovirus genotypes in, 179
  liver, candidates for, hepatitis C virus genotypes in, 448
  peripheral blood progenitor cell, cytomegalovirus infection monitoring in, 1490
Treponema pallidum infection, diagnosis, clinical vs. laboratory, 583
Triamcinolone, doxycycline with, for *Chlamydia trachomatis* genital infection, macaque model, 648
Tribute, Jay P. Sanford (February 1997)
Tropical spastic paraparesis, human T cell lymphotropic/leukemia virus type 1 antibodies in, 716
Trypanosoma brucei brucei, interferon-γ–stimulated proliferation, tyrosine kinases in, mouse model, 669
Trypanosoma cruzi, antibodies to, long-lasting, 1272
Tuberculosis
  bacterial antigen, T cell receptor activation, in HIV infection, 429
  diagnosis, ESAT-6 antigen detection in, cattle model, 1251
  epidemiology, Arkansas, 1440
  in HIV infection, virus-bacterial potentiation in, in vitro model, 1531
  risk
    in pregnancy, 1025
    in white men, 1535

Tumor necrosis factor-α
in bactericidal/permeability-increasing protein release, 108
brain cell response to, 478
cerebrospinal fluid, in subacute sclerosing panencephalitis, 689
production
autologous platelet interaction in, 123
in coxsackievirus group B vascular endothelial cell infection, 693
in *Entamoeba histolytica* liver abscess, gerbil model, 1176
factors affecting, in macrophage culture, 1008
in fever of unknown origin, 191
in HIV infection, 1507
vs. disease progression, 47
in pentoxifylline therapy, for HIV infection, 1210
in septic shock, circadian time structure, 1283
promoter region polymorphisms in, in HIV infection, 188
Typhoid fever, vaccination, with antimalarial drugs and other vaccines, 871
Tyrosine kinases, in interferon-γ–stimulated *Trypanosoma brucei brucei* proliferation, mouse model, 669

UL97 region, cytomegalovirus, antiviral susceptibilities, 1087
Ulcers, in HIV infection
esophageal, pathogenesis, 1216
genital, diagnosis, clinical vs. laboratory, 583
oral, opportunistic viruses in, 1324
Urethritis, screening and management, East African men, 833
Urinary tract infection, *Escherichia coli*
adhesin genes in, epidemiology, 983
PapG adhesins, receptor specificities, 373
sexual transmission, 989
Urine culture, in cytomegalovirus infection prediction, in HIV infection, 302
Uropathogens, sexual transmission, 989

Vaccination
bacille Calmette-Gúerin, in poliomyelitis eradication program, S268
Bordetella pertussis, immunodominant domains in, 1423
Borrelia burgdorferi, mouse model, 91, 400
cholera, with antimalarial drugs and other vaccines, 871
diphtheria–tetanus toxoid–pertussis, in poliomyelitis eradication program, S268
hepatitis B
mutation emergence in, chimpanzee model, 511
nonresponders, 678
with yeast recombinant vaccine, in elderly persons, 1494
Yupik Eskimos, 674
herpes simplex virus type 2, genetically inactivated, 16
human immunodeficiency virus
mouse model, 292
neutralization activity studies in, 764
human T cell lymphotropic/leukemia virus type I, 716
influenza
of health care workers, reduced mortality in elderly patients, 1
heat-labile enterotoxin adjuvant for, 352
purified recombinant hemagglutinin in, 342
malaria, in Tanzania, 921
measles
in passively acquired antibody presence, macaque model, 524
in poliomyelitis eradication program, S268, S272
meningococci
group B, animal models, 364
polysaccharide-protein conjugate in, 200
mumps, Urabe vaccine strain, molecular characterization, 1548
Neisseria meningitidis
animal models, 364
serogroup C, mouse model, 84
pneumococcal, *Streptococcus pneumoniae* colonization after, in HIV infection, 590
poliomyelitis (*see* Poliomyelitis vaccination)
respiratory syncytial virus
group B, cotton rat model, 932
maternal, infant protection in, guinea pig model, 935
rotaviruses, heterotypic protection after, mouse model, 330
rubella, with low antibody levels, 749
streptococci, group B, mouse model, 1237
Streptococcus pneumoniae
in HIV infection, 975
mouse model, 839
typhoid, with antimalarial drugs and other vaccines, 871
vaccinia, immune response to, vs. administration route, 756
varicella, dose titration study, 444
yellow fever, with antimalarial drugs and other vaccines, 871
Vaccinia vaccination, immune response to, vs. administration route, 756
Vagina
Escherichia coli colonization, perinatal complications from, 606
immunoglobulin induction in, in HIV intranasal immunization, mouse model, 292
Vaginal discharge
HIV shedding in, vertical transmission, 57
HIV-specific IgA in, 265
Vaginosis, bacterial, microorganism symbiotic relationship in, 406
Vancomycin
intravitreal, for methicillin-resistant *Staphylococcus epidermidis* endophthalmitis, rabbit model, 462
resistance to, *Enterococcus faecalis* BM4281, 598
Varicella-zoster virus, vaccines, dose titration study, 444
Vascular cell adhesion molecule-1, expression, in *Rickettsia conorii* infection, 1142
Vascular endothelial cells, coxsackievirus group B infection, 693
Venezuelan equine encephalitis, epidemiology, Colombia, 828
Vibrio cholerae
O1 El Tor, molecular characterization, in Calcutta, India, 1134
vaccination, with antimalarial drugs and other vaccines, 871
Virulence factors
Cryptococcus neoformans, phospholipase activity, mouse model, 414
Escherichia coli
adhesin molecules, 983
uropathic, receptor specificities, 373
Rickettsia conorii, 1142
Shigella, macrophage apoptosis induction, 470
Visceral leishmaniasis, acquired resistance in, mouse model, 1477
Vitamin A deficiency
HIV vertical transmission and, 57
supplements for, in poliomyelitis eradication program, Philippines, S272
Vulvar cancer, condylomata acuminata and, 743
VX-478 protease inhibitor, for HIV infection, glycoprotein binding in, 1063

Waterborne infection
Mycobacterium avium, in simian immunodeficiency virus infection, 184
poliomyelitis, S286
Western blot test
for *Borrelia burgdorferi*, antibodies cross-reacting with, 466
for hepatitis C virus antibody response, recombinant phage, 26
Whooping cough
helper T cell activation in, 1246

vaccination, immunodominant domains in, 1423
Wild polioviruses (*See* Polioviruses, wild)
Women (*see also* Pregnancy)
condylomata acuminata in, cancer and, 743
HIV infection in
mucosal immune response in, 265
virus burden in, in early stage, 795
World Health Assembly, poliomyelitis eradication initiative (*see* Poliomyelitis eradication)
World Health Organization, polio surveillance laboratory network, S113, S117
Wound infection, *Serratia marcescens*, epidemiology, California, 992
Wuchereria bancrofti, circulating antigen, treatment effects on, 489

Yellow fever, vaccination, with antimalarial drugs and other vaccines, 871
Yersinia enterocolitica, in T cells, in reactive arthritis, 1121

Zalcitabine, for HIV infection, 1344
response monitoring in, 1202
zidovudine with, in pediatric patients, 1039
Zidovudine, for HIV infection
cerebrospinal fluid viral DNA levels and, 434
vs. didanosine, 255
didanosine and lamivudine with, 1051
efficacy
quantitative virologic measures for, 247
surrogate markers for, 237
mother-to-infant transmission prevention, 971
nucleoside analogues with, 1344
resistance to, 1502
response monitoring in, 1202
virus susceptibility to, 561
zalcitabine with, in pediatric patients, 1039
Zymosan, serum-treated, in bactericidal/permeability-increasing protein release, 108